



Centers for Disease Control and Prevention

NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL

Rigorous Evaluation of Strategies to Prevent Overdose through Linking People with Illicit
Substance Use Disorders to Recovery Support Services

RFA-CE-22-010

03/14/2022

Table of Contents

Section I. Funding Opportunity Description	6
Section II. Award Information.....	24
Section III. Eligibility Information.....	25
Section IV. Application and Submission Information.....	30
Section V. Application Review Information	39
Section VI. Award Administration Information.....	49
Section VII. Agency Contacts	61
Section VIII. Other Information	62

Overview

Participating Organization(s)

Centers for Disease Control and Prevention

Components of Participating Organizations

Components of Participating Organizations:

National Center for Injury Prevention and Control

Notice of Funding Opportunity (NOFO) Title

Rigorous Evaluation of Strategies to Prevent Overdose through Linking People with Illicit Substance Use Disorders to Recovery Support Services

Activity Code

Applications in response to this Notice of Funding Opportunity (NOFO) will be funded using the R01 activity code for a research grant.

Notice of Funding Opportunity Type

New

Agency Notice of Funding Opportunity Number

RFA-CE-22-010

Assistance Listings Number(s)

93.136

Category of Funding Activity

HL - Health

NOFO Purpose

The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will support the identification and rigorous evaluation of effective strategies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community, and, if needed, re-link people to such services following resumption of illicit

substance use. Research is needed to evaluate strategies that are tailored to the individual to increase recovery capital, defined as tangible and intangible resources that one possesses before substance use, during substance use and will likely be available in the future, and maintain recovery, or initiate return to care, among people with illicit substance use disorders through linkage to programs and services that help support recovery over time (i.e., recovery support services). Recovery support services can improve the quality of personal relationships among patients with illicit substance use disorders, increase the number of low-risk people in their social networks, and provide access to tangible resources such as training and employment opportunities to support and sustain their long-term recovery. For the purposes of this Notice of Funding Opportunity (NOFO), “recovery ecosystem” is defined as available recovery support services in a community tailored to the needs of the individual. Linkage to recovery ecosystems to meet individual needs may include connecting people to multiple recovery support services that work together, potentially multiple times, and rigorous evaluation can help to identify replicable strategies to accomplish such linkages. The focus of this NOFO is on understanding the effectiveness of strategies to link people who are in recovery, or re-link people following resumption of illicit substance use, to recovery support services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual. This NOFO is intended to support research on the following objective: **Conduct a process and outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, re-link people to such services following resumption of illicit substance use.** A rigorous evaluation, inclusive of both a process and outcome evaluation, should be conducted to evaluate the effectiveness of the linkage strategies that facilitate continued access to a recovery ecosystem on impacting key health outcomes, including, but not limited to, maintaining recovery, re-linking people to care, and preventing overdose.

Key Dates

Publication Date:

To receive notification of any changes to RFA-CE-22-010, return to the synopsis page of this announcement at www.grants.gov and click on the "Send Me Change Notification Emails" link. An email address is needed for this service.

Letter of Intent Due Date:

01/17/2022

Letters of Intent are requested by **1/17/2022**. Although a letter of intent is not required, is not binding, and does not enter into the review of an application, the information that it contains assists NCIPC with planning for scientific and technical merit peer review.

Application Due Date:

03/14/2022

Applications are due on the listed application due date at 5:00PM EST. Please carefully review and follow the instructions in *Section IV. Application and Submission Information 9. Submission Dates and Times* in order to ensure timely receipt of your application by the listed application due date at 5:00PM EST.

On-time submission requires that electronic applications be error-free and made available to CDC for processing from the NIH eRA system on or before the deadline date. Applications must

be submitted to and validated successfully by Grants.gov no later than 5:00 PM U.S. Eastern Time.

Applicants will use a system or platform to submit their applications through Grants.gov and eRA Commons to CDC. ASSIST, an institutional system to system (S2S) solution, or Grants.gov Workspace are options. ASSIST is a commonly used platform because it provides a validation of all requirements prior to submission and prevents errors.

For more information on accessing or using ASSIST, you can refer to the ASSIST Online Help Site at: <https://era.nih.gov/erahelp/assist>. Additional support is available from the NIH eRA Service desk via <http://grants.nih.gov/support/index.html>.

- E-mail: commons@od.nih.gov
- Phone: 301-402-7469 or (toll-free) 1-866-504-9552.
Hours: Monday - Friday, 7 a.m. to 8 p.m. Eastern Time, excluding Federal holidays.

Note: HHS/CDC grant submission procedures do not provide a grace period beyond the application due date time to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).

Scientific Merit Review:

06/14/2021

This is an estimated date.

Secondary Review:

08/23/2021

This is an estimated date.

Estimated Start Date:

09/30/2022

September 30, 2022

Expiration Date:

03/22/2022

Required Application Instructions

It is critical that applicants follow the instructions in the [How to Apply - Application Guide](#) except where instructed to do otherwise in this NOFO. Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Note: The Research Strategy component of the Research Plan is limited to 20 pages.

Page Limitations: Pages that exceed the page limits described in this NOFO will be removed and not forwarded for peer review, potentially affecting an application's score.

Applications that do not comply with these instructions may be delayed or may not be accepted for review.

Telecommunications for the Hearing Impaired: TTY 1-888-232-6348

Executive Summary

Purpose

The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will support the identification and rigorous evaluation of effective strategies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community, and, if needed, re-link people to such services following resumption of illicit substance use. Research is needed to evaluate strategies that are tailored to the individual to increase recovery capital, defined as tangible and intangible resources that one possesses before substance use, during substance use and will likely be available in the future, and maintain recovery, or initiate return to care, among people with illicit substance use disorders through linkage to programs and services that help support recovery over time (i.e., recovery support services). Recovery support services can improve the quality of personal relationships among patients with illicit substance use disorders, increase the number of low-risk people in their social networks, and provide access to tangible resources such as training and employment opportunities to support and sustain their long-term recovery. For the purposes of this Notice of Funding Opportunity (NOFO), “recovery ecosystem” is defined as available recovery support services in a community tailored to the needs of the individual. Linkage to recovery ecosystems to meet individual needs may include connecting people to multiple recovery support services that work together, potentially multiple times, and rigorous evaluation can help to identify replicable strategies to accomplish such linkages. The focus of this NOFO is on understanding the effectiveness of strategies to link people who are in recovery, or re-link people following resumption of illicit substance use, to recovery support services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual. This NOFO is intended to support research on the following objective: **Conduct a process and outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, re-link people to such services following resumption of illicit substance use.** A rigorous evaluation, inclusive of both a process and outcome evaluation, should be conducted to evaluate the effectiveness of the linkage strategies that facilitate continued access to a recovery ecosystem on impacting key health outcomes, including, but not limited to, maintaining recovery, re-linking people to care, and preventing overdose.

Mechanism of Support: The funding mechanism for this Notice of Funding Opportunity (NOFO) will be a research grant (R-01).

Funds Available and Anticipated Number of Awards: CDC/NCIPC intends to commit up to \$3,750,000 in FY 2022 to fund up to five (5) applications. Awards issued under this NOFO are contingent upon availability of funds and a sufficient number of meritorious applications.

Budget and Project Period: The maximum award amount will be \$750,000 per award for the first 12-month budget period. This includes both direct and indirect costs.

Applicants may request a project period of up to three (3) years. The maximum total project funding is \$2,250,000 (direct and indirect) per award, over the project period. The project period

is expected to be 09/30/2022 to 09/29/2025. The total award will depend upon the project quality, duration, and cost proposed.

Application Research Strategy Length: Page limits for the Research Strategy are clearly specified in *Section IV. Application and Submission Information* of this announcement.

Eligible Institutions/Organizations: Institutions/organizations listed in *Section III. Eligibility Information 1. Eligible Applicants* are eligible to apply.

Eligible Project Directors/Principal Investigators (PDs/PIs): CDC does not make awards to individuals directly. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply.

Applications in which the contact Eligible PD/PI meets NIH Early Stage Investigator (ESI) status, as verified via the [NIH Determination of Investigator Status](#) process, **and** whose application has a meritorious peer review score, may be considered for prioritization during the second level of review (see *Section V. Application Review Information 4. Review and Selection Process*). For the contact PD/PI [Determination of Investigator Status](#):

- Prior to application submission, PD/PIs are encouraged to verify and/or enter the date of their terminal research degree or the end date of their post-graduate clinical training in their eRA Commons Profile to ensure the correct identification. NIH systems will automatically calculate the status of each investigator and display it within their eRA Commons personal profile. The ESI status of the PD/PIs on any R01 or R01 equivalent application will be flagged at time of submission. Investigators should make sure their status is correctly marked in their profile. If your status is incorrect, please contact the [NIH eRA Service Desk](#).

Number of PDs/PIs: An application may name more than one PD/PI; their names must appear on the face page of the application. However:

- One (1) principal investigator must be designated as the contact PD/PI for all correspondence related to the application.
- All PD/PIs must include their eRA Commons Identification in the Credential Field of the Senior/Key Person Profile Component of the SF-424 (R&R) Application Package.
- Institutions/organizations proposing multiple PDs/PIs must visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF-424 (R&R) Application Guide.

Number of Applications: Eligible applicant organizations may submit more than one application to this NOFO, provided that each application is scientifically distinct. However, applicant institutions can submit only one application with the same contact PD/PI. Only one application per contact PD/PI will be funded under this announcement. If two or more applications from the same contact PD/PI are received for this NOFO, the only application that

will be submitted for review will be the last application received based on the document's time and date stamp in Grants.gov (<http://www.grants.gov>). The applicant must ensure that duplicate applications are withdrawn prior to the application review date.

Additionally, applicant institutions submitting applications with essentially the same proposed research to two or more CDC/ATSDR NOFOs will not be funded under more than one NOFO.

Application Type: NEW

Special Date(s): A pre-application teleconference call will not be conducted for this NOFO. Applicant questions to clarify information in the text of this NOFO during the NOFO open period are strongly encouraged. Please contact via email the Scientific/Research Contact, Peer Review Contact, or the Financial/Grants Management Contact listed in *Section VII. Agency Contacts* with questions. All applicant questions (personal or application related identifying information redacted) received by January 20, 2022 and NCIPC responses to these questions will be included in an amended NOFO that will be published approximately by **January 27, 2022**. Please see *Section VII. Agency Contacts* for specific contact information.

Application Materials: See *Section IV.1* for application materials.

Section I. Funding Opportunity Description

Statutory Authority

Section 301 (a) [42 U.S.C. 241(a)] of the Public Health Service Act, and Section 391 (a)[42 U.S.C. 280b(a)] of the Public Health Service Act, as amended.

1. Background and Purpose

In 2017, the opioid crisis was declared a public health emergency.¹ Deaths due to drug overdose have continued to increase, contributing to 70,630 deaths in 2019,² and provisional data indicate deaths increased to over 90,000 in 2020.³ Overdose deaths accelerated during the COVID-19 pandemic, with rapid increases in deaths involving synthetic opioids excluding methadone, likely illicitly manufactured fentanyl (IMF), and increases in overdose deaths involving stimulants such as methamphetamine and cocaine.⁴ Data from the first six months of 2019 show that nearly 85% of overdose deaths involved IMFs, heroin, cocaine or methamphetamine, and highlights the importance of intervention opportunities for persons who use illicit drugs.⁵

In 2019, 8.3 million people age 12 and older reported having an illicit drug use disorder and 1.6 million reported specifically having an opioid use disorder.⁶ Among those reporting an illicit drug use disorder, 28% reported receiving treatment, and among those reporting an opioid use disorder, 18% reported receiving medications for opioid use disorder (MOUD), a treatment found to be effective in reducing illicit opioid use and preventing overdose.⁷ Although the illegal nature of illicit drug use more generally precludes an accurate understanding of the extent of use and the adverse outcomes among individuals and in communities,⁸ these numbers indicate the importance of linking people with illicit substance use disorders to care. However, linking an individual to treatment for illicit substance use disorders only represents the beginning of the recovery process. For example, in 2018, the percentage of persons who completed publicly

funded treatment was 42%; 20% were transferred for additional treatment; and 25% did not complete treatment.⁹ Indeed, illicit substance use disorders are considered to be “chronic, relapsing disorder[s]”¹⁰, and this understanding has become more common among those in the field of substance use.¹¹ **Therefore, linkage to illicit substance use disorder treatment can be complemented by linkage to recovery support services and re-linkage to care when needed.** There is a need to coordinate continuity of care following completion of formal treatment services, linking treatment to recovery support services that account for individual needs and community capacity.¹²⁻¹⁴ Given the potential for resumption of illicit substance use during the course of recovery from illicit substance use disorders, the concept of continuity of care can benefit from incorporating reconnecting people with illicit substance use disorders to recovery support services if needed.

Recovery can be impacted by factors across levels of the social ecology. Indeed, CDC applies a public health approach to its overdose prevention efforts, recognizing that there are risk and protective factors at each level of the social ecological model that influence an individual’s potential for illicit substance use and recovery. At the **individual level**, substance use disorder treatment clinicians identified young age and limited life experience as risks for negative outcomes.¹⁵ A study among healthcare professionals found that drug of choice (i.e., major opioids defined as fentanyl, morphine, meperidine, methadone, heroin and controlled-release oxycodone), coexisting psychiatric illness, and family history of substance use disorders are associated with resumption of substance use.¹⁶ A lack of motivation can contribute to challenges to recovery,¹⁵ while believing in a disease model of addiction and having an abstinence goal are associated with attending self-help meetings following treatment.¹³ Research also shows that co-use of opioids and stimulants is associated with suboptimal treatment outcomes.¹⁷ Further, injection and smoking may confer greater severity of substance use disorders compared to intranasal use, which could in turn impact retention in treatment.^{18, 19} At the **interpersonal level**, personal and social relationships are key priorities for recovery,²⁰ and may not always facilitate recovery if substance use is reinforced through relationships.²¹ Normative drug use in social networks and a lack of knowledge about treatment can hinder recovery^{15, 22} while having low-risk friends or friends who support abstinence can confer protective effects that increase over time after treatment and encourage involvement in self-help groups.^{13, 22} People who use substances may also have limited networks;²¹ thus recovery support systems often incorporate a component aimed at building supportive social networks.^{14, 23} At the **institutional level**, people in recovery may encounter social service clinicians with high caseloads that limit access and time during visits.¹⁵ Parole or probation officers may not have training on MOUD and therefore may not be aware of the benefits of such treatment.¹⁵ This is particularly important considering in 2019 nearly one-third of people on probation or on parole/supervised release reported illicit drug use in the past year²⁴ and a recent qualitative study with people in this population found the highest priority among participants was substance use recovery.²⁵ Where one lives can also be important. For example, living in group housing is positively associated with self-help involvement after treatment.¹³ At the **community level**, stigma or a lack of support treatment centers and self-help meetings can represent challenges to recovery.^{13, 15} Community-based support can help to increase self-acceptance and access to support networks that include recreational activities as well assistance identifying affordable housing options.¹⁴ Important considerations at this level also include transportation¹⁵ and employment.²⁰ A review of the literature found that people treated for substance use disorders experience a higher rate of

unemployment compared to the national unemployment rate and that there is evidence that unemployment increases the risk of resuming substance use.²⁶ **Societal level** factors that can influence risk for resuming illicit substance use or maintaining recovery includes policies implemented within workplaces that are supportive of recovery,²⁷ policies that improve access to opioid use disorder and substance use disorder treatment,²⁸ and policies that divert individuals from the criminal justice system to substance use disorder treatment.²⁹ Effective recovery ecosystems (defined as available recovery support services in a community tailored to the needs of the individual) can reduce risk factors and promote protective factors across the social ecology, and the linkages designed to connect and reconnect people within such ecosystems can help ensure successful long-term recovery from illicit substance use disorders. **Therefore, approaches to support recovery from illicit substance use disorders may require linkage to several intervention components across the social ecology such as unemployment, housing and family services, and reentry services for people who were recently released from incarceration, in addition to treatment for substance use, mental health conditions and medical problems,³⁰ and linkage may be required multiple times.** All of these features comprise the concept of recovery capital, originally defined as tangible and intangible resources that one possesses before substance use, during substance use and will likely be available in the future.³¹

Best et al ³² further broke recovery capital into three types: personal, social, and community. Personal resources can go beyond access to treatment; understanding the strengths, interests and life goals among people in treatment for substance use disorders can help build personal recovery capital.¹⁴ Social describes resources available to groups of people in recovery and community describes resources available to individuals and groups within the community. Emphasized is that the right kind of supports are needed for recovery, and recovery is linked to families and communities. Best et al ³² describe a system of care that nests positive relationships within a supportive community.³² The American Society of Addiction Medicine (ASAM) asserts that a comprehensive treatment plan must be informed by an assessment of a patient's needs, including with regard to their support system.³³ By discerning where the support system is lacking, interventions and service settings can be tailored to the individual. **Capacity to facilitate linkage to a continuum of care and a recovery ecosystem that supports individual needs is required. This represents opportunities to leverage interventions that link people with illicit substance use disorders to support services and increase recovery capital and re-link them if needed.**

These services may be described as recovery support services²³ or continuing care³⁴ that address support at multiple levels, from emotional to tangible, such as linkages to jobs and housing as well as recreation and involvement in meaningful activities.^{23, 34} This kind of approach can facilitate increases in recovery capital. ³¹ Some of the most prominent examples of recovery support services include Peer Based Recovery Support Services, Recovery Community Centers, Recovery Support Services in Educational Settings, Mutual-Help Organizations, Recovery Housing and Clinical Models of Continuing Care.²³ The level of evidence among these approaches varies, ranging from limited to strong. Continuing care services include Mindfulness-Based Relapse Prevention, Telephone-Based Continuing Care, Recovery Management Checkups, and Continuing Care Based on Physician Health Programs.³⁴ Access to multiple recovery support services and continuing care can support or comprise a recovery ecosystem that

addresses risk and protective factors at multiple levels of the social ecology. For example, Peer Based Recovery may provide emotional support at the individual level.²³ Recovery Community Centers and Mutual-Help Organizations can impact the interpersonal level through fostering peer groups that are supportive of recovery. Clinical Models of Continuing Care can enhance support at the institutional level, and Recovery Housing, Recovery Community Centers and Mutual-Help Organizations can foster a positive environment that provides support at both the community and system level. Further, social determinants of health (SDOH), or the conditions in which people live, work, learn, and play, can also contribute to health inequities.³⁵ Specifically, limited access to quality healthcare, experiencing racism or discrimination within a community or living in an unsafe neighborhood are examples of SDOH that can confer intergenerational risk for substance use and overdose.³⁶⁻⁴⁰ Services designed to address long-standing systemic social and health inequities may help improve access to resources for some members of disproportionately affected groups.⁴¹ **Availability of recovery support services may vary by community, and support needs may vary by individual; therefore, linkage strategies must allow for flexibility in the number and type of available services, with the goal of connecting people in recovery for substance use disorders to all available recovery support services that support their individual needs.**

Purpose:

The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will support the identification and rigorous evaluation of effective strategies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community, and, if needed, re-link people to such services following resumption of illicit substance use. The focus of this Notice of Funding Opportunity (NOFO) is on understanding the effectiveness of evidenced-based strategies to link people who are in recovery, or re-link people following resumption of illicit substance use, to services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual. This NOFO is intended to support research on the following objective: Conduct a process and outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use.

Applications will be funded for a maximum of \$750,000 per year for a project period of up to three years.

NCIPC intends to fund applications evaluating the effectiveness of linkage strategies, programs, and policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support services available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use through both a process evaluation and an outcome evaluation. Of particular interest is research that focuses on communities experiencing disproportionate burden of illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or

quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose). The focus on these groups aims to ensure that research advances knowledge among varied populations at risk for overdose. NCIPC intends to fund applications that focus on these populations. Research that examines effectiveness of strategies in high burden areas (e.g., identified through high overdose rates or vulnerability assessments) or that addresses health equity and is tailored for populations at greatest risk or with least access is also encouraged. Additional anticipated long-term outcomes of this funding include increased translation of research to practice, and enhanced capacity of states and communities.

Minority Serving Institutions: This NOFO seeks diversity among applicant institutions, research investigators, and partnering organizations to ensure researcher experience and research outcomes are applicable and beneficial to all segments of our population and social ecology. Applicants from or collaborating with Minority Serving Educational Institutions (MSIs) representative of and serving the community participating in the evaluation are highly encouraged. For the purpose of this NOFO, MSIs include Hispanic Serving Institutions (HSIs), Historically Black Colleges and Universities (HBCUs), Tribal Colleges and Universities (TCUs), and Alaska Native and Native Hawaiian Serving Institutions, as defined by the [U.S. Department of Education](#). Meritorious applications from eligible MSIs or eligible institutions collaborating with MSIs, as evidenced by MSI inclusion in the SF-424 Senior/Key Personnel form, may be considered during the second level of review to broaden distribution of awards (see *Section V. Application Review Information 4. Review and Selection Process*).

Applications must propose to conduct **both a process evaluation and an outcome evaluation** of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use. **Applications submitted that do not include both a clearly defined process evaluation and a clearly defined outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use, as evidenced by the Research Strategy section of the application’s research plan, will not be recommended for funding consideration during the NCIPC second level review (See *Section V. Application Review Information 4. Review and Selection Process*).**

References

1. HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis. Department of Health and Human Services; 2017.
2. Hedegarrd HM, AM Warner, M. Drug overdose deaths in the United States, 1999-2019. 2020;394(Dec 2020)
3. 12 Month-ending Provisional Number of Drug Overdose Deaths (2021).

4. Centers for Disease Control and Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. *CDC Health Action Network*. 2020;December 17
5. O'Donnell J, Gladden M, Mattson C, Hunter C, Davis N. Vital signs: Characteristics of drug overdose deaths involving opioids and stimulants — 24 states and the District of Columbia, January–June 2019. *Morbidity & Mortality Weekly Report*. 2020;69(35):1189-1197.
6. HHS Publication No. PEP20-07-01-001 Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration) (2020).
7. Medications for Opioid Use Disorder, Treatment Improvement Protocol 63 (Substance Abuse and Mental Health Services Administration,) (2020).
8. Campa A, Martinez SS, Baum M. Drug Addiction, Relapse and Recovery. *Journal of Drug Abuse*. 2017;3(1):4.
9. Treatment Episode Data Set (TEDS): 2018. Admissions to and discharges from publicly-funded substance use treatment (Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration) (2020).
10. Drugs, Brains, and Behavior: The Science of Addiction (National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services) (2018).
11. Dennis M, Scott CKJAS. Managing addiction as a chronic condition. *J Addiction Science Clinical Practice*. 2007;4(1):45.
12. Xuan Z, Choi J, Lofbrutto L, et al. Support services for young adults with substance use disorders. *Pediatrics*. 2021;147(Supplement 2):S220-S228.
13. Mankowski ES, Humphreys K, Moos RH. Individual and contextual predictors of involvement in twelve-step self-help groups after substance abuse treatment. *American Journal of Community Psychology*. 2001;29(4):537-563.
14. McKay JR. Making the hard work of recovery more attractive for those with substance use disorders. *Addiction*. 2017;112(5):751-757.
15. Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. *Addiction science & clinical practice*. 2018;13(1):1-10.
16. Domino KB, Hornbein TF, Polissar NL, et al. Risk factors for relapse in health care professionals with substance use disorders. *Jama*. 2005;293(12):1453-1460.
17. Tsui JI, Mayfield J, Speaker EC, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. *Journal of Substance Abuse Treatment*. 2020;109:80-85. doi:10.1016/j.jsat.2019.10.005
18. Gossop M, Griffiths P, Powis B, Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. *Addiction*. 1992;87(11):1527-1536. doi:10.1111/j.1360-0443.1992.tb02660.x
19. Gossop M, Griffiths P, Powis B, Strang J. Cocaine: Patterns of Use, Route of Administration, and Severity of Dependence. *British Journal of Psychiatry*. 2018;164(5)(5):660-664. doi:10.1192/bjp.164.5.660
20. Laudet AB, White WJJoSAT. What are your priorities right now? Identifying service needs across recovery stages to inform service development. 2010;38(1):51-59.
21. Weston S, Honor S, Best D. A tale of two towns: a comparative study exploring the possibilities and pitfalls of social capital among people seeking recovery from substance misuse.

Substance Use & Misuse. 2018;53(3):490-500.

22. Eddie D, Kelly JF. How many or how much? Testing the relative influence of the number of social network risks versus the amount of time exposed to social network risks on post-treatment substance use. *Drug and Alcohol Dependence*. 2017/06/01/ 2017;175:246-253.

doi:<https://doi.org/10.1016/j.drugalcdep.2017.02.012>

23. Recovery Research Institute. *Report of findings from a systematic review of the scientific literature on recovery support services in the United States*. 2017.

24. HHS Publication No. PEP20-07-01-001 Results from the 2019 National Survey on Drug Use and Health: Table 6.27B (Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration) (2020).

25. Dong KR, Must A, Tang AM, Beckwith CG, Stopka TJ. Competing priorities that rival health in adults on probation in Rhode Island: substance use recovery, employment, housing, and food intake. *BMC Public Health*. 2018;18(1):1-10.

26. Henkel D. Unemployment and substance use: a review of the literature (1990-2010). *Current drug abuse reviews*. 2011;4(1):4-27.

27. Centers for Disease Control and Prevention. Workplace Supported Recovery. National Institute for Occupational Safety and Health. 05/26/2021,

<https://www.cdc.gov/niosh/topics/opioids/wsrp/default.html>

28. United States Congress. H.R.2634 - Drug Addiction Treatment Act of 2000. 05/26/2021, <https://www.congress.gov/bill/106th-congress/house-bill/2634>

29. Lindquist-Grantz R, Mallow P, Dean L, Lydenberg M, Chubinski J. Diversion Programs for Individuals Who Use Substances: A Review of the Literature. *Journal of Drug Issues*. 2021:00220426211000330.

30. Jemberie WB, Williams JS, Eriksson M, et al. Substance use disorders and COVID-19: multi-faceted problems which require multi-pronged solutions. *Frontiers in Psychiatry*. 2020;11

31. Granfield R, Cloud W. *Coming clean: Overcoming addiction without treatment*. New York University Press; 1999.

32. Best D, Irving J, Collinson B, Andersson C, Edwards M. Recovery networks and community connections: Identifying connection needs and community linkage opportunities in early recovery populations. *Alcoholism Treatment Quarterly*. 2017;35(1):2-15.

33. Guide for future directions for the addiction and OUD treatment ecosystem (Discussion Paper) (National Academy of Medicine) (2021).

34. McKay JR. Impact of Continuing Care on Recovery From Substance Use Disorder. *Alcohol research: current reviews*. 2021;41(1)

35. Centers for Disease Control and Prevention. Social Determinants of Health: Know What Affects Health. Centers for Disease Control and Prevention. 10/26/2021,

<https://www.cdc.gov/socialdeterminants/index.htm>

36. Merrick MT, Ford DC, Haegerich TM, Simon T. Adverse Childhood Experiences Increase Risk for Prescription Opioid Misuse. *J Prim Prev*. Apr 2020;41(2):139-152. doi:10.1007/s10935-020-00578-0

37. Wade R, Jr., Cronholm PF, Fein JA, et al. Household and community-level Adverse Childhood Experiences and adult health outcomes in a diverse urban population. *Child Abuse Negl*. Feb 2016;52:135-45. doi:10.1016/j.chiabu.2015.11.021

38. Liebling EJ, Yedinak JL, Green TC, Hadland SE, Clark MA, Marshall BD. Access to substance use treatment among young adults who use prescription opioids non-medically. *Subst Abuse Treat Prev Policy*. Nov 29 2016;11(1):38. doi:10.1186/s13011-016-0082-1

39. Scheidell JD, Quinn K, McGorray SP, et al. Childhood traumatic experiences and the association with marijuana and cocaine use in adolescence through adulthood. *Addiction*. Jan 2018;113(1):44-56. doi:10.1111/add.13921
40. Swedo EA, Sumner SA, de Fijter S, et al. Adolescent Opioid Misuse Attributable to Adverse Childhood Experiences. *J Pediatr*. Sep 2020;224:102-109 e3. doi:10.1016/j.jpeds.2020.05.001
41. Centers for Disease Control and Prevention. Using a Health Equity Lens. Centers for Disease Control and Prevention, 10/26/2021, https://www.cdc.gov/healthcommunication/Health_Equity_Lens.html
42. Puddy, R. W. & Wilkins, N. (2011). Understanding Evidence Part 1: Best Available Research Evidence. A Guide to the Continuum of Evidence of Effectiveness. Atlanta, GA: Centers for Disease Control and Prevention
43. Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What's Working in the United States. Centers for Disease Control and Prevention. 12/1/2021, <http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf>

Healthy People 2030 and other National Strategic Priorities

This research addresses the **Healthy People 2030** focus areas of Substance Use and Injury Prevention as described in: <https://health.gov/healthypeople>. Specifically, this NOFO supports the Healthy People Substance Use (SU) areas of SU-03 Reduce drug overdose deaths, SU-07 Reduce the proportion of adults reporting use of any illicit drugs during the past 30 days, and SU-15 Reduce the proportion of people with illicit drug use disorder in the past year. This research also supports the Healthy People Injury Prevention (IVP) area of IVP-20 Reduce overdose deaths involving opioids, and IVP-03 Reduce unintentional injury deaths.

Public Health Impact

The proposed research is expected to expand the evidence base for the effectiveness of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to evidence-based recovery support services available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use.

Linkage strategies, programs, or policies evaluated as a result of this NOFO have the potential to prevent illicit substance use and fatal and nonfatal overdose, increase maintenance of recovery from illicit substance use disorders, and increase return to care for illicit substance use disorders. Additionally, strategies, programs, or policies evaluated as part of this NOFO have the potential to increase recovery capital among people with illicit substance use disorders, regardless of where they are in their process of recovery, through connecting them to recovery support services available within their community that meet their individual needs.

Relevant Work

The strategic plan for the Division of Overdose Prevention includes the goal: Reduce opioid overdose now. The current concept applies to these goals.

This proposal also aligns with the current research priorities of the Division of Overdose Prevention. This project addresses the following research priority: Develop and evaluate innovative prevention strategies designed to prevent overdose, including among those at greatest risk.

The following publications from Division of Overdose Prevention authors have been recently released:

1. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. [Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019](#). MMWR Morb Mortal Wkly Rep 2021;70:202–207.
2. Liu S, Scholl L, Hoots B, Seth P. [Nonfatal Drug and Polydrug Overdoses Treated in Emergency Departments — 29 States, 2018–2019](#). MMWR Morb Mortal Wkly Rep 2020;69(34):1149–1155.
3. Haegerich T, Jones C, Cote PO, Robinson A, Ross L. [Evidence for State, Community and Systems-Level Prevention Strategies to Address the Opioid Crisis](#)^{external icon}. *Drug and Alcohol Dependence*. 2019; doi:10.1016/j.drugalcdep.2019.107563

CDC currently funds 66 jurisdictions as part of its Overdose Data to Action Program (<https://www.cdc.gov/drugoverdose/od2a/index.html>), a cooperative agreement that began in September 2019. The program is focused on the complex and changing nature of the drug overdose epidemic, including stimulant overdoses, and highlights the need for an interdisciplinary, comprehensive, and cohesive public health approach to preventing overdoses.

2. Approach

NCIPC intends to fund applications evaluating the effectiveness of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, re-link people to such services following resumption of illicit substance use. The application **must present the best available research evidence undergirding the recovery support service(s)** identified in the community, including the outcomes the services have been demonstrated to impact and the level of rigor of the research designs (e.g., randomized controlled trials, quasi-experimental designs) establishing the effectiveness of the selected recovery support service(s).⁴² **At least one of the recovery support services must meet the following criteria for evidence-based:** 1) meta-analyses or systematic reviews have found the strategy to be effective at reducing overdose and/or factors that increase overdose risk; (2) evidence from a scientifically rigorous experimental study, such as a randomized controlled trial, demonstrates the strategy’s effectiveness in reducing overdose and/or factors that increase overdose risk; or (3) multiple observational studies from U.S. settings indicate the strategy’s ability to reduce overdose or mitigate and reduce factors that increase overdose risk.⁴³

The evaluation must include **both** a process evaluation and an outcome evaluation, since process evaluation results can provide context and inform the results of the outcome evaluation (e.g., by documenting whether strategies were implemented as planned and whether expected output was actually produced). Linkage strategies, programs, or policies evaluated can be existing, new, or adapted.

A rigorous evaluation, inclusive of both a process and outcome evaluation, should be conducted to evaluate the effectiveness of the linkage strategies that facilitate continued access to a

recovery ecosystem on impacting key health outcomes, including, but not limited to, maintaining recovery, re-linking people to care, and preventing overdose. The process evaluation should describe barriers and facilitators to implementation, the extent to which the program was implemented as designed, and whether the program was accessible and acceptable to the population served by the linkage strategies. **Applications submitted that do not include both a clearly defined process evaluation and a clearly defined outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use, as evidenced by the Research Strategy section of the application’s research plan, will not be recommended for funding consideration during the NCIPC second level review (See *Section V. Application Review Information 4. Review and Selection Process*)**

The proposed research is expected to focus on linkage strategies, programs, and policies that aim to increase recovery capital among people with illicit substance use disorders, regardless of where they are in their process of recovery, through connecting them to evidence-based recovery support services. Applicants **must** clearly describe in the application the proposed implementation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, re-link people to such services following resumption of illicit substance use. **Applications that do not propose the implementation of linkage strategies, programs, or policies that link people in recovery for illicit substance used disorders to at least one recovery support service, as evidenced in the Research Strategy section of the application’s research plan, will be considered nonresponsive and will not be forwarded for peer review.** The proposed research should include a focus on understanding the effectiveness of strategies to link people who are in recovery to services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual. Applicants are expected to incorporate linking people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available in their community as part of their linkage strategy, with the understanding that the recovery support service or services will vary according to the needs of the individual. Recovery ecosystems may include linkages to multiple recovery support services and depending on the needs of the individual and the services available in the community, linkage to recovery ecosystems may include connecting people to varying multiple support services, potentially multiple times. Rigorous evaluation can help to identify replicable strategies to accomplish such linkages and can help to identify linkage strategies to connect people who are in recovery to services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual. Connecting people to existing services can help to maximize the use of services already available within a community. This approach may help to inform translation to other communities. Such strategies can also help to address structural inequalities. Outcome evaluations should examine the effectiveness of the linkage strategies that facilitate access to an individualized recovery ecosystem on key health outcomes, including, but not limited to, maintaining recovery, re-linking people with care, and preventing overdose.

The goal of the proposed research is to understand the impact that linkage to multiple recovery support services has on the creation of a recovery ecosystem that addresses risk and protective

factors across the social ecology based on individual needs and increases in recovery capital. **Applicants are expected to propose research that links, or re-links, people to recovery support services across the social ecology and link, or re-link, people to at least one recovery support service that is evidence-based. In addition, applicants are expected to propose research linking, or re-linking, people to recovery support services that create a recovery ecosystem that goes beyond solely providing medical services such as inpatient or outpatient treatment for substance use, mental health conditions or other medical problems.** The creation of a recovery ecosystem could incorporate a focus on SDOH through linkage to intervention components including but not limited to unemployment, housing and family services, reentry services for people who were recently released from incarceration, potentially in addition to inpatient or outpatient treatment for substance use, mental health conditions and other medical problems. **Applications that propose evaluating strategies, programs or policies linking, or re-linking, people to recovery support services that solely focus on medical services and do not also link to other recovery support services will not be considered for funding during the NCIPC second level of review (See Section V. Application Review Information 4. Review and Selection Process).**

The proposed research may include evaluation of strategies involving a collaboration between public safety and public health components focused on enhancing linkage of people in recovery for illicit substance use disorders to recovery support services available within their community and, if needed, *re-linkage* of people to such services following resumption of illicit substance use. However, research funds are not available to solely evaluate the effectiveness of public safety programs. **Applications that solely evaluate the effectiveness of a public safety program without also including, as a primary aim, evaluation of at least one public health component focused on linking people in recovery for illicit substance use disorders to recovery support services, as evidenced by the Research Strategy section of the application's research plan, will be considered nonresponsive and will not be forwarded for peer review.**

Applications proposing to evaluate law enforcement or criminal justice responses without inclusion of a strong public health component, as a primary research aim, as evidenced by the application's SF-424 Research Strategy section of the application's research plan, Specific Aims section, will be considered nonresponsive and will not be forwarded for peer review.

Applications are highly encouraged to evaluate the effectiveness of linkage strategies that incorporate social-ecological theoretical frameworks that address multiple measures, outcomes and health inequities at the individual, relationship, community, and societal levels (Solar, 2010).

Applicants should propose to conduct **both** a process and an outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support services available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use that are being developed or under implementation. However, applicants are reminded that this NOFO is a research notice of funding opportunity and not a stand-alone program development announcement. **Therefore, applicants cannot propose to implement a linkage strategy**

without also conducting a rigorous research evaluation of the linkage strategy. All applications will be evaluated during the peer review process on the strength of the research question, the appropriateness of the research question in addressing the scientific intent of the NOFO, the strength of the research design and approach in order to answer the research question, and the feasibility of completing the proposed research within the time frame of the project period and within the proposed budget, among other scored peer review criteria as described in *Section V. Application Review Information Criteria*. **Applications that propose to implement linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one recovery support service without also conducting a research evaluation of the linkage strategy, as evidenced by the Research Strategy section of the application's research plan, will be considered nonresponsive and will not be forwarded for peer review.**

For the purpose of this NOFO, "implementation" refers to the process used to initiate a linkage strategy, program, or policy into practice and the process used to sustain an existing strategy or intervention in practice. The process and outcome evaluations are expected to consider the initiation and/or continuation of the linkage strategy, program, or policy in place throughout the project period.

Applications are expected to propose a rigorous evaluation design: experimental (i.e., randomized controlled trials) and quasi-experimental designs (e.g., designs involving matched comparison groups, designs using propensity-score matching, instrumental variable methods, regression point displacement, regression discontinuity, or time series designs) methods. All applications are expected to provide data analytic plans that are appropriate to the linkage strategy, research design, hypotheses, data collection measures, and project period. Investigators are expected to anticipate, evaluate, and address threats to the internal and external validity of the specified research design. It is expected that the application's approach will apply strong study designs that incorporate methods, design protocols, and measures to facilitate dissemination, implementation, and translation research questions. Such questions could include a focus on how protocol quality and adherence can be strengthened, how linkage strategies, programs or policies can be adapted for different populations, how available services can be maximized within community capacity, the core components that are essential to achieve the desired outcome, the factors that moderate the ability of the linkage strategy, program or policy to be effective, the cultural norms and expectations that support effectiveness, the readiness for change needed to adequately support implementation, the acceptability and appropriateness for different contexts, the cost considerations for implementation, and so forth.

NCIPC intends to fund applications that focus on communities experiencing disproportionate burden of illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose). Applications may include both a focus on populations

experiencing high rates of overdose *and* a plan to evaluate the effectiveness of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to recovery support services available within their community. Research that examines effectiveness of strategies in high burden areas (e.g., identified through high overdose rates or vulnerability assessments) or that addresses health equity and is tailored for populations at greatest risk or with least access is also encouraged.

CDC places a priority on studies that generate findings that can immediately be translated into action to shorten the time lag between development and scale-up. Applicants are expected to develop a translation plan for the research findings. Applicants are encouraged to review the **Translation Plan** section below for information on the expectations for the translation plan.

The proposed research must focus on human subjects. **Applications proposing research using non-human species will be considered nonresponsive and will not be forwarded for peer review.**

Applications must be responsive to **all** responsiveness criteria in NOFO RFA-CE-22-010 in order to be forwarded for peer review. Additional responsiveness criteria are listed in *Section III. Eligibility Information 5. Responsiveness* of this NOFO. It is the applicant's responsibility to ensure that the submitted research proposal meets **all** responsiveness criteria listed in *Section III. Eligibility Information 5. Responsiveness*.

Objectives/Outcomes

The primary goal of this research is to determine the effectiveness of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support services available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use. Primary outcomes to be achieved with funded research should directly contribute to our understanding of how such linkage strategies, programs, or policies can prevent illicit substance use and fatal and nonfatal overdose, maintenance of recovery from illicit substance use disorders, and return to care for illicit substance use disorders if needed. Research that examines effectiveness of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to recovery support services available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use in communities experiencing disproportionate burden of illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose) is especially encouraged. The focus on these groups aims to ensure that research advances knowledge among varied populations at risk for overdose. Research that examines effectiveness of strategies in high burden areas (e.g., identified through high overdose rates or vulnerability assessments) or that addresses health equity and is tailored for populations at greatest risk or with least access is also encouraged.

Outcomes of interest can include, but are not limited to:

- fatal and nonfatal drug overdose
- illicit substance use
- maintenance of recovery from illicit substance use disorders
- return to care for illicit substance use disorders and recovery support services more broadly if needed

Secondary outcomes of interest can include, but are not limited to:

- quality of interpersonal relationships
- composition of social networks with respect to illicit substance use

Outcomes are expected to be measured during the project period.

Process measures of interest can include, but are not limited to:

- barriers and facilitators to implementation
- extent to which the program was implemented as designed
- accessibility and acceptability by the population served by the linkage strategies

Data collection, acquisition, and analysis

Applicants must identify and describe appropriate data sources and provide evidence of their ability to acquire and/or collect data of sufficient quantity and quality to conduct the proposed research within the two-year project period. Applications should clearly describe and justify the proposed sampling methods, sample size, power estimates, and data collection methods for the primary outcome(s), at a minimum, and other proposed secondary measures and subgroup analyses. The timeline for data acquisition (requests for extant data and or primary data collection) must be specified. Numerous data sources can be used for the outcome data, including emergency department data, law enforcement data, self-report data, and other sources of data. In addition, administrative data from relevant agencies and survey data collected prior to or in the context of the evaluation are potential sources. Appropriate data sources will vary by the proposed research approach and outcome measures. The outcome(s) should be measured at the level consistent with the research focus (e.g., federal, state, local, or organizational), the population of interest and the data sources available or collected for the purposes of this project (e.g., administrative, survey, surveillance, hospital or emergency departments, detention facilities, etc.).

Protection of Human Subjects and Personally Identifiable Information

The Research Strategy section of the application is expected to clearly describe the type, source, access to, and protections of the data and human subjects participating in the study. Access to non-publicly available, previously collected data must be clearly described in the Research Strategy and documented with a signed Data Sharing Agreement or Letter of Support. Access to publicly available, previously collected data must be clearly described in the Research Strategy.

Protection of previously collected data includes, but is not limited to, protection of personally identifiable information from loss and/or misuse.

The application is expected to identify each performance site that will be conducting human subjects research and include the FWA number for the applicant institution and each performance site. Research conducted with more than one institution will be expected to use a single Institutional Review Board (sIRB) to conduct the ethical review required by HHS regulations. See *Section IV. Application and Submission Information, 10 Funding Restrictions, Human Subjects* for details.

Target Population

The target population includes youth or adults with illicit substance use disorders, regardless of where they are in the process of recovery. People at higher risk of overdose may also be considered, including people with past nonfatal overdoses and incarcerated populations. Research focused on communities experiencing disproportionate burden of illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose) is encouraged. Research that examines effectiveness of strategies in high burden areas (e.g., identified through high overdose rates or vulnerability assessments) or that addresses health equity and is tailored for populations at greatest risk or with least access is also encouraged.

Collaboration/Partnerships

It is expected that for all applications, the applicant organization and contact PI will provide the scientific and technical leadership necessary to conduct the proposed research throughout the entire project period. It is expected that the proposed research work plan described in the Research Strategy section of the application and the SF-424 Research and Related Budget will demonstrate the applicant organization's leadership and involvement throughout the entirety of the project period. The applicant organization cannot serve as a "pass through" to fund another entity to conduct the majority of the research or provide the scientific or technical leadership necessary to complete the proposed research project.

This initiative is intended to encourage collaboration of scientists from a spectrum of disciplines including public health, health professionals, epidemiology, law enforcement, social work, economics, and criminal justice. Collaboration and partnership with community and/or governmental organizations from multiple sectors (e.g., health, social services, law enforcement, criminal justice) that can provide access to populations at highest risk for illicit stimulant use and overdose and provide access to critical data systems is encouraged. Collaboration with investigators that are from underrepresented backgrounds, such as underrepresented racial and ethnic groups is also encouraged. Applicants are expected to partner with organizations that serve people with illicit substance use disorders. These may include treatment providers such as primary care physicians who prescribe medications for opioid use disorder, behavioral health

specialists, or providers in inpatient settings as well as community-based providers of services to people with illicit substance use disorders. Applicants are also encouraged to seek and include the meaningful involvement of communities, including state and/or local health departments, local governmental agencies and/or businesses, and community-based organizations in the development and conduct of the proposed research, and in the translation and dissemination of research results.

Partnerships between the applicant institution and outside entities may be necessary or advantageous to complete the proposed work. If partnerships are proposed, the application must clearly describe roles and responsibilities of each partnering entity. This includes demonstration of the applicant’s access to planned data sources and study populations, and all partnerships necessary to complete the proposed project.

The Research Strategy section of the application is expected to clearly describe the roles and responsibilities of each research team member individually and each participating entity. This includes describing how the partnership will allow the applicant to complete the proposed work. The Research Strategy section of the application must clearly describe the nature and extent of the proposed partnership, including the roles and responsibilities of the Principal Investigator(s) and of the outside entities or partner agencies, the existing working relationship, plans for the proposed research, the nature and extent of the involvement to be provided by the applicant institution and outside entity, the outside entity's scope of work, and how the partnership will ensure implementation and sustainability of the proposed evaluation. The Research Strategy section must clearly describe all data sources and the partnerships that are in place to assure data access for all proposed analyses to be completed within the project period.

The roles and responsibilities described for each partnering entity must be substantiated with a signed Data Sharing Agreement, Letter of Support (LOS), or Memorandum of Understanding (MOU), and be included in the Letter of Support section of the application. The Data Sharing Agreement, Letter of Support (LOS), or Memorandum of Understanding (MOU) must describe the partner’s commitment of resources, time, and personnel to the proposed research. Applications that do not include a signed Data Sharing Agreement, Letter of Support, or Memorandum of Understanding from each partnering entity may not be recommended for funding (see *Section V. Application Review Information, 4 Review and Selection Process*).

Applications will be evaluated during peer review on:

- The extent to which the Research Strategy section clearly describes the roles and responsibilities of each partner involved in data collection and/or the effectiveness evaluation.
- The extent to which the Research Strategy clearly describes the working relationships between the applicant institution and all partner organizations.
- The extent to which the Research Strategy clearly describes the involvement and scope of work each partner is willing to complete to ensure the success of the proposed research within the proposed project period.

- The extent to which the relationships and activities of the partnerships described in the Research Strategy, are documented by a signed Data Sharing Agreement, Letter of Support, or Memorandum of Understanding that clearly delineates the intent and capabilities of each partnership.

Applications that do not include a signed Data Sharing Agreement, Letter of Support, or Memorandum of Understanding from each partnering entity or source of data described in the Research Strategy section of the application may not be recommended for funding (see *Section V. Application Review Information, 4 Review and Selection Process*). It is incumbent on the applicant to clearly describe each contribution of each partnership to the proposed research in the Research Strategy and document the intent and capabilities of each partnership with a signed Data Sharing Agreement, Letter of Support, or Memorandum of Understanding.

Minority Serving Institutions

This NOFO seeks diversity among applicant institutions, research investigators, and partnering organizations to ensure researcher experience and research outcomes are applicable and beneficial to all segments of our population and social ecology. Applicants from or collaborating with Minority Serving Educational Institutions (MSIs) representative of and serving the community participating in the evaluation are highly encouraged. For the purpose of this NOFO, MSIs include Hispanic Serving Institutions (HSIs), Historically Black Colleges and Universities (HBCUs), Tribal Colleges and Universities (TCUs), and Alaska Native and Native Hawaiian Serving Institutions, as [defined by the U.S. Department of Education](#). Meritorious applications from eligible MSIs or eligible institutions collaborating with MSIs, as evidenced by MSI inclusion in the SF-424 Senior/Key Personnel form, may be considered during the second level of review to broaden distribution of awards (see *Section V. Application Review Information 4. Review and Selection Process*).

This NOFO encourages the inclusion of early-stage investigators as members of the SF-424 Senior/Key Personnel research team to help build experience and expertise in illicit substance use, substance use disorders, or overdose prevention research.

Applications should demonstrate that the research staff have the necessary skills and experience to ensure quality and timeliness of proposed activities. The participation of students and other researchers-in-training is encouraged. Applicants planning to incorporate training and/or mentorship roles into their research activities should describe the plans for the recruitment, training, and supervision of trainees/mentees and the ongoing quality assurance of their scientific products.

Evaluation/Performance Measurement

Applicants are expected to rigorously evaluate linkage strategies, programs, or policies link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, re-link people to such services following resumption of drug use. The focus of this work is on understanding the effectiveness of strategies to link people who are in recovery, or re-link people following resumption of illicit substance use, to services across the social ecology that are available in their community to comprise a recovery ecosystem tailored to the needs of the individual; **therefore, most of the**

application should be dedicated to describing the approach proposed for rigorous evaluation, the evaluation plan, and measurement issues. Evaluation of the proposed project itself, that is, the degree to which a funded project is meeting its recruitment, implementation, data acquisition, and management goals will be aided by a detailed project workplan and timeline, accompanied by discussion of how unanticipated delays or adverse events of any kind will be handled. Applicants may evaluate secondary outcomes, such as the approach's impact on risk and protective factors, if feasible, and if those additional activities do not compromise the evaluation of the main outcomes of the NOFO. Applicants are also encouraged to examine aspects of the linkage strategy approach, such as implementation and cost, as well as the effectiveness of the approach by subgroups, such as groups disproportionately affected by illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose). Research that examines effectiveness of strategies in high burden areas (e.g., identified through high overdose rates or vulnerability assessments) or that addresses health equity and is tailored for populations at greatest risk or with least access is also encouraged.

Translation Plan

The application is expected to clearly describe the potential for widespread dissemination, implementation, and sustainability of the proposed program, policy, or practice. Research findings should be disseminated through publications, including articles in peer reviewed scientific journals, and "Research Briefs" for diverse audiences, as well as presentations at professional conferences, and in institutional and community-based venues.

When relevant to the goals of the research project, the PI should describe how the significant findings may be used to promote, enhance, or advance translation of the research into practice or may be used to inform public health policy. In particular, the PI should describe how the intervention is designed to address key drivers of health inequities, e.g., through focusing on disproportionately affected populations and/or how it can be tailored for other populations that might be at high risk for overdose. Disproportionately affected populations may include persons experiencing a disproportionate burden of substance use disorders and overdose, including but not limited, to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose. If relevant, describe how the results of this project could be generalized to populations and communities outside of the study.

Applicants should also include plans to appropriately document the program, policy, or practice

implementation methods as well as lessons learned to facilitate future replication in another research or non-research setting if the prevention strategy is found to be effective. These plans may include but are not limited to identifying the core components of the program, policy, or practice and documenting lessons learned from the study that might inform decisions about future adaptation or modification of the strategy for other settings or populations.

Grant recipients will be required to attend one reverse site visit per year in Atlanta with CDC/NCIPC staff during the period of performance to review their progress and findings and to discuss opportunities for widespread dissemination of their research achievements and lessons learned. Travel costs for attending this meeting must be included in the application's travel budget submitted in response to this NOFO.

3. Funding Strategy

N/A

Section II. Award Information

Funding Instrument Type:

G (Grant)

A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed:

New - An application that is submitted for funding for the first time. Includes multiple submission attempts within the same round.

Estimated Total Funding:

\$11,250,000

Anticipated Number of Awards:

5

Awards issued under this NOFO are contingent on the availability of funds and submission of a sufficient number of meritorious applications.

Award Ceiling:

\$750,000

Per Budget Period

Award Floor:

\$0

Per Budget Period

Total Period of Performance Length:

3 year(s)

Throughout the Period of Performance, CDC's commitment to continuation of awards will depend on the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports), and CDC's determination that continued funding is in the best interest of the Federal government.

HHS/CDC grants policies as described in the HHS Grants Policy Statement (<https://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf>) will apply to the applications submitted and awards made in response to this NOFO.

If you are successful and receive a Notice of Award, in accepting the award, you agree that the award and any activities thereunder are subject to all provisions of 45 CFR Part 75, currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Section III. Eligibility Information

1. Eligible Applicants

Eligibility Category:

99 (Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility")

25 (Others (see text field entitled "Additional Information on Eligibility" for clarification))

22 (For profit organizations other than small businesses)

23 (Small businesses)

20 (Private institutions of higher education)

13 (Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education)

12 (Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education)

11 (Native American tribal organizations (other than Federally recognized tribal governments))

08 (Public housing authorities/Indian housing authorities)

07 (Native American tribal governments (Federally recognized))

06 (Public and State controlled institutions of higher education)

05 (Independent school districts)

04 (Special district governments)

02 (City or township governments)

00 (State governments)

01 (County governments)

Additional Eligibility Category:

The following types of Higher Education Institutions are always encouraged to apply for CDC support as Public or Private Institutions of Higher Education:

Hispanic-serving Institutions

Alaska Native and Native Hawaiian Serving Institutions

Historically Black Colleges and Universities (HBCUs)

Tribally Controlled Colleges and Universities (TCCUs)

Nonprofits (Other than Institutions of Higher Education):

Nonprofits (Other than Institutions of Higher Education)

Other:

Faith-based or Community-based Organizations

Bona Fide Agents: A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with "Other Attachment Forms."

Federally Funded Research and Development Centers (FFRDCs): FFRDCs are operated, managed, and/or administered by a university or consortium of universities, other not-for-profit or nonprofit organization, or an industrial firm, as an autonomous organization or as an identifiable separate operating unit of a parent organization. A FFRDC meets some special long-term research or development need which cannot be met as effectively by an agency's existing in-house or contractor resources. FFRDC's enable agencies to use private sector resources to accomplish tasks that are integral to the mission and operation of the sponsoring agency. For more information on FFRDCs, go to <https://gov.ecfr.io/cgi-bin/searchECFR>.

Regional Organizations

2. Foreign Organizations

Foreign Organizations **are not** eligible to apply.

Foreign components of U.S. Organizations are not eligible to apply.

For this announcement, applicants may not include collaborators or consultants from foreign institutions. All applicable federal laws and policies apply.

3. Additional Information on Eligibility

See *Section III. Eligibility Information*

4. Justification for Less than Maximum Competition

Not Applicable (N/A)

5. Responsiveness

It is the applicant's responsibility to ensure that the application meets all responsiveness criteria listed in this section. Applications that do not meet all of the following responsiveness criteria will be considered nonresponsive and will not be forwarded for peer review. There must

be an overall match between the proposed research objectives as described in the applicant's abstract and the research objectives of this announcement as described in Section I under the heading, "Objectives/Outcomes."

- **Applications that do not propose the implementation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one recovery support service, as evidenced in the Research Strategy section of the application's research plan, will be considered nonresponsive and will not be forwarded for peer review.**
- **Applications that propose to implement linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one recovery support service without also conducting a research evaluation of the linkage strategy, as evidenced in the Research Strategy section of the application's research plan, will be considered nonresponsive and will not be forwarded for peer review.**
- **Applications that solely evaluate the effectiveness of a public safety program without also including, as a primary aim, evaluation of at least one public health component focused on linking people in recovery for illicit substance use disorders to recovery support services, as evidenced by the Research Strategy section of the application's research plan, will be considered nonresponsive and will not be forwarded for peer review.**
- **Applications proposing to evaluate law enforcement or criminal justice responses without inclusion of a strong public health component, as a primary research aim, as evidenced by the application's SF-424 Research Strategy section of the application's research plan, Specific Aims section, will be considered nonresponsive and will not be forwarded for peer review.**
- **The proposed research must focus on human subjects. Applications proposing research using non-human species will be considered nonresponsive and will not be forwarded for peer review.**

The SF-424 Biographical Sketch for the PI or Co-Investigator(s) must include documentation of expertise in the area of illicit substance use, substance use disorders, or overdose or by serving as the contact PD/PI on a research grant in the area of illicit substance use, substance use disorders, or overdose. The knowledge, experience, and expertise necessary to conduct this research and achieve proposed objectives must be documented with at least one first-authored, peer-reviewed publication as defined by the [NIH National Library of Medicine](#) in the relevant area of illicit substance use, substance use disorders, or overdose prevention, or by serving as a principal investigator on a research grant in the area of illicit substance use, substance use disorders, or overdose research. Experience requirements may be demonstrated through the combined experiences of a Principal and Co-Investigator (if applicable). The citation of the relevant publication(s) or research experience must be clearly identified (by bold text or highlight) in the appropriate SF 424 Biographical Sketch. **Applications that do not include documentation to meet this requirement will be considered non-responsive and will not be forwarded for peer review.**

6. Required Registrations

Applicant organizations must complete the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.

PLEASE NOTE: For applications due on or after April 4, 2022, applicants must have a unique entity identifier (UEI) at the time of application submission. In preparation for the federal government's April 4, 2022, transition from the Data Universal Numbering System (DUNS) to the Unique Entity Identifier (UEI), applicants must obtain a UEI. The UEI is generated as part of SAM.gov registration. Current SAM.gov registrants have already been assigned their UEI and can view it in SAM.gov and grants.gov. Additional information is available on the [GSA website](#), [SAM.gov](#), and [Grants.gov-Finding the UEI](#).

- (Foreign entities only): Special Instructions for acquiring a Commercial and Governmental Entity (NCAGE) Code:
[https://eportal.nspa.nato.int/AC135Public/Docs/US Instructions for NSPA NCAGE.pdf](https://eportal.nspa.nato.int/AC135Public/Docs/US%20Instructions%20for%20NSPA%20NCAGE.pdf)
- System for Award Management (SAM) – must maintain current registration in SAM (the replacement system for the Central Contractor Registration) to be renewed annually, [SAM.gov](#).
- [Grants.gov](#)
- [eRA Commons](#)

All applicant organizations must register with Grants.gov. Please visit www.Grants.gov at least 30 days prior to submitting your application to familiarize yourself with the registration and submission processes. The one-time registration process will take three to five days to complete. However, it is best to start the registration process at least two weeks prior to application submission.

All Senior/Key Personnel (including Program Directors/Principal Investigators (PD/PIs) must also work with their institutional officials to register with the eRA Commons or ensure their existing Principal Investigator (PD/PI) eRA Commons account is affiliated with the eRA commons account of the applicant organization. All registrations must be successfully completed and active before the application due date. Applicant organizations are strongly encouraged to start the eRA Commons registration process at least four (4) weeks prior to the application due date. ASSIST requires that applicant users have an active eRA Commons account in order to prepare an application. It also requires that the applicant organization's Signing Official have an active eRA Commons Signing Official account in order to initiate the submission process. During the submission process, ASSIST will prompt the Signing Official to enter their Grants.gov Authorized Organizational Representative (AOR) credentials in order to complete the submission, therefore the applicant organization must ensure that their Grants.gov AOR credentials are active.

7. Universal Identifier Requirements and System for Award Management (SAM)

All applicant organizations **must obtain** a DUN and Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the Universal Identifier when applying for Federal grants or cooperative agreements. The DUNS number is a nine-digit number assigned by Dun and Bradstreet Information Services. An AOR should be consulted to determine the appropriate number. If the organization does not have a DUNS number, an AOR should complete the [US D&B D-U-N-S Number Request Web Form](#) or contact Dun and Bradstreet by telephone directly at 1-866-705-5711 (toll-free) to obtain one. A DUNS number will be provided immediately by telephone at no charge. Note this is an organizational number. Individual Program Directors/Principal Investigators do not need to register for a DUNS number.

PLEASE NOTE: For applications due on or after April 4, 2022, applicants must have a unique entity identifier (UEI) at the time of application submission. In preparation for the federal government's April 4, 2022, transition from the Data Universal Numbering System (DUNS) to the Unique Entity Identifier (UEI), applicants must obtain a UEI. The UEI is generated as part of SAM.gov registration. Current SAM.gov registrants have already been assigned their UEI and can view it in SAM.gov and grants.gov. Additional information is available on the [GSA website](#), [SAM.gov](#), and [Grants.gov-Finding the UEI](#).

Additionally, all applicant organizations must register in the **System for Award Management (SAM)**. Organizations must maintain the registration with current information at all times during which it has an application under consideration for funding by CDC and, if an award is made, until a final financial report is submitted or the final payment is received, whichever is later. SAM is the primary registrant database for the Federal government and is the repository into which an entity must provide information required for the conduct of business as a recipient. Additional information about registration procedures may be found at the SAM internet site at [SAM.gov](#) and the [SAM.gov Knowledge Base](#).

If an award is granted, the recipient organization **must** notify potential sub-recipients that no organization may receive a subaward under the grant unless the organization has provided its DUNS number to the recipient organization.

8. Eligible Individuals (Project Director/Principal Investigator) in Organizations/Institutions

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for HHS/CDC support.

9. Cost Sharing

This NOFO does not require cost sharing as defined in the HHS Grants Policy Statement (<http://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf>).

10. Number of Applications

As defined in the HHS Grants Policy Statement, (<https://www.hhs.gov/sites/default/files/grants/grants/policies->

[regulations/hhsgps107.pdf](#)), applications received in response to the same Notice of Funding Opportunity generally are scored individually and then ranked with other applications under peer review in their order of relative programmatic, technical, or scientific merit. HHS/CDC will not accept any application in response to this NOFO that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application.

Eligible applicant organizations may submit more than one application to this NOFO, provided that each application is scientifically distinct. However, applicant institutions can submit only one application with the same contact PD/PI. Only one application per contact PD/PI will be funded under this announcement. If two or more applications from the same contact PD/PI are received for this NOFO, the only application that will be submitted for review will be the last application received based on the document's time and date stamp in Grants.gov (<http://www.grants.gov>). The applicant must ensure that duplicate applications are withdrawn prior to the application review date.

Additionally, applicant institutions submitting applications with essentially the same proposed research to two or more CDC/ATSDR NOFOs will not be funded under more than one NOFO.

Section IV. Application and Submission Information

1. Address to Request Application Package

Applicants will use a system or platform to submit their applications through Grants.gov and eRA Commons to CDC. ASSIST, an institutional system to system (S2S) solution, or Grants.gov Workspace are options. ASSIST is a commonly used platform because, unlike other platforms, it provides a validation of all requirements prior to submission and prevents errors.

To use ASSIST, applicants must visit <https://public.era.nih.gov> where you can login using your eRA Commons credentials, and enter the Notice of Funding Opportunity Number to initiate the application, and begin the application preparation process.

If you experience problems accessing or using ASSIST, you can refer to the ASSIST Online Help Site at: <https://era.nih.gov/erahelp/assist>. Additional support is available from the NIH eRA Service desk via: <http://grants.nih.gov/support/index.html>

- Email: commons@od.nih.gov
- Phone: 301-402-7469 or (toll-free) 1-866-504-9552.
Hours: Monday - Friday, 7 a.m. to 8 p.m. Eastern Time, excluding Federal holidays.

2. Content and Form of Application Submission

Applicants must use FORMS-G application packages for due dates on or after April 4, 2022 and must use FORMS-F application packages until April 3, 2022.

Application guides for FORMS-F and FORMS-G application packages are posted to the [How to Apply - Application Guide](#) page.

It is critical that applicants follow the instructions in the SF-424 (R&R) Application Guide [How to Apply - Application Guide](#) except where instructed in this Notice of Funding Opportunity to

do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review. The package associated with this NOFO includes all applicable mandatory and optional forms. Please note that some forms marked optional in the application package are required for submission of applications for this NOFO. Follow the instructions in the SF-424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.

When using ASSIST, all mandatory forms will appear as separate tabs at the top of the Application Information screen; applicants may add optional forms available for the NOFO by selecting the Add Optional Form button in the left navigation panel.

Please use the form and instructions for SF424 (R&R) Form F. Applicants must use FORMS-F application packages until April 3, 2022.

3. Letter of Intent

Due Date for Letter Of Intent 01/17/2022

01/17/2022

A letter of intent is requested by **January 17, 2022**. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCIPC staff to estimate the potential review workload and plan the review. By the date listed above and in *Part 1. Overview Information*, prospective applicants are asked to submit a letter of intent that includes the following information:

- Name of the applicant (organization)
- Description of the research topic
- Descriptive title of the proposed research
- Name, address, and telephone number of the contact PD/PI
- Name of other key personnel
- Participating institutions
- Number and title of this notice of funding opportunity announcement (NOFO)

The letter of intent should be sent electronically to:

Mikel Walters, PhD
Scientific Review Official
Extramural Research Program Operations
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
Email: mwalters@cdc.gov

4. Required and Optional Components

A complete application has many components, both required and optional. The forms package associated with this NOFO in Grants.gov includes all applicable components for this NOFO, required and optional. In ASSIST, all required and optional forms will appear as separate tabs at the top of the Application Information screen.

5. PHS 398 Research Plan Component

The SF424 (R&R) Application Guide includes instructions for applicants to complete a PHS 398 Research Plan that consists of components. Not all components of the Research Plan apply to all Notices of Funding Opportunities (NOFOs). Specifically, some of the following components are for Resubmissions or Revisions only. See the SF 424 (R&R) Application Guide at [How to Apply - Application Guide](#) for additional information. Please attach applicable sections of the following Research Plan components as directed in Part 2, Section 1 (Notice of Funding Opportunity Description).

Follow the page limits stated in the SF 424 unless otherwise specified in the NOFO. As applicable to and specified in the NOFO, the application should include the bolded headers in this section and should address activities to be conducted over the course of the entire project, including but not limited to:

1. **Introduction to Application** (for Resubmission and Revision ONLY) - provide a clear description about the purpose of the proposed research and how it addresses the specific requirements of the NOFO.
2. **Specific Aims** – state the problem the proposed research addresses and how it will result in public health impact and improvements in population health.
3. **Research Strategy** – the research strategy should be organized under 3 headings: Significance, Innovation and Approach. Describe the proposed research plan, including staffing and time line.
4. **Progress Report Publication List** (for Continuation ONLY)

Other Research Plan Sections

5. **Vertebrate Animals**
6. **Select Agent Research**
7. **Multiple PD/PI Leadership Plan.**
8. **Consortium/Contractual Arrangements**
9. **Letters of Support**
10. **Resource Sharing Plan(s)**
11. **Authentication of Key Biological and/or Chemical Resources**
12. **Appendix**

All instructions in the SF424 (R&R) Application Guide at [How to Apply - Application Guide](#) must be followed along with any additional instructions provided in the NOFO.

Applicants that plan to collect public health data must submit a Data Management Plan (DMP) in the Resource Sharing Plan section of the PHS 398 Research Plan Component of the application. A DMP is required for each collection of public health data proposed. Applicants who contend that the public health data they collect or create are not appropriate for release must justify that contention in the DMP submitted with their application for CDC funds.

The DMP may be outlined in a narrative format or as a checklist but, at a minimum, should include:

- A description of the data to be collected or generated in the proposed project;
- Standards to be used for the collected or generated data;
- Mechanisms for, or limitations to, providing access to and sharing of the data (include a description of provisions for the protection of privacy, confidentiality, security, intellectual property, or other rights - this section should address access to identifiable and de-identified data);
- Statement of the use of data standards that ensure all released data have appropriate documentation that describes the method of collection, what the data represent, and potential limitations for use; and
- Plans for archiving and long-term preservation of the data, or explaining why long-term preservation and access are not justified (this section should address archiving and preservation of identifiable and deidentified data).

CDC OMB approved templates may be used (e.g. NCCDPHP template <https://www.cdc.gov/chronicdisease/pdf/nofo/DMP-Template-508.docx>)

Other examples of DMPs may be found here: USGS, <http://www.usgs.gov//products/data-and-tools/data-management/data-management-plans>

Applicants must use FORMS-G application packages for due dates on or after April 4, 2022 and must use FORMS-F application packages until April 3, 2022.

Application guides for FORMS-F and FORMS-G application packages are posted to the [How to Apply - Application Guide](#) page.

Please use the form and instructions for SF424 (R&R) Form F. Applicants must use FORMS-F application packages until April 3, 2022.

6. Appendix

Do not use the appendix to circumvent page limits. A maximum of 10 PDF documents are allowed in the appendix. Additionally, up to 3 publications may be included that are not publicly available. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

Do not use the appendix to circumvent page limits. A maximum of 10 PDF documents are allowed in the appendix. Additionally, up to 3 publications may be included that are not publicly available. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

Up to 5 PDF files of supporting materials for the Research Plan may also be included in the appendix as described below (7. Page Limitations). The appendix has a total maximum page limit of 25 pages.

7. Page Limitations

All page limitations described in this individual NOFO must be followed. For this specific NOFO, the Research Strategy component of the Research Plan narrative is limited to 20 pages. Supporting materials for the Research Plan narrative included as appendices may not exceed 10 PDF files with a maximum of 25 pages for all appendices. Pages that exceed page limits described in this NOFO will be removed and not forwarded for peer review, potentially affecting an application's score.

8. Format for Attachments

Designed to maximize system-conducted validations, multiple separate attachments are required for a complete application. When the application is received by the agency, all submitted forms and all separate attachments are combined into a single document that is used by peer reviewers and agency staff. Applicants should ensure that all attachments are uploaded to the system.

CDC requires all text attachments to the Adobe application forms be submitted as PDFs and that all text attachments conform to the agency-specific formatting requirements noted in the SF424 (R&R) Application Guide at [How to Apply - Application Guide](#).

Applicants must use FORMS-G application packages for due dates on or after April 4, 2022 and must use FORMS-F application packages until April 3, 2022.

Application guides for FORMS-F and FORMS-G application packages are posted to the [How to Apply - Application Guide](#) page.

Please use the form and instructions for SF424 (R&R) Form F. Applicants must use FORMS-F application packages until April 3, 2022.

9. Submission Dates & Times

Part I. Overview Information contains information about Key Dates. Applicants are strongly encouraged to allocate additional time and submit in advance of the deadline to ensure they have time to make any corrections that might be necessary for successful submission. This includes the time necessary to complete the application resubmission process that may be necessary, if errors are identified during validation by Grants.gov and the NIH eRA systems. The application package is not complete until it has passed the Grants.gov and NIH eRA Commons submission and validation processes. Applicants will use a platform or system to submit applications.

ASSIST is a commonly used platform because it provides a validation of all requirements prior to submission. If ASSIST detects errors, then the applicant must correct errors before their application can be submitted. Applicants should view their applications in ASSIST after submission to ensure accurate and successful submission through Grants.gov. If the submission is not successful and post-submission errors are found, then those errors must be corrected and the application must be resubmitted in ASSIST.

Applicants are able to access, view, and track the status of their applications in the eRA Commons.

Information on the submission process is provided in the SF-424 (R&R) Application Guidance and ASSIST User Guide at https://era.nih.gov/files/ASSIST_user_guide.pdf.

Note: HHS/CDC grant submission procedures do not provide a grace period beyond the grant application due date time to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).

Applicants who encounter problems when submitting their applications must attempt to resolve them by contacting the NIH eRA Service desk at:

Toll-free: 1-866-504-9552; Phone: 301-402-7469

<http://grants.nih.gov/support/index.html>

Hours: Mon-Fri, 7 a.m. to 8 p.m. Eastern Time (closed on Federal holidays)

Problems with Grants.gov can be resolved by contacting the Grants.gov Contact Center at:

Toll-free: 1-800-518-4726

<https://www.grants.gov/web/grants/support.html>

support@grants.gov

Hours: 24 hours a day, 7 days a week; closed on Federal holidays

It is important that applicants complete the application submission process well in advance of the due date time.

After submission of your application package, applicants will receive a "submission receipt" email generated by Grants.gov. Grants.gov will then generate a second e-mail message to applicants which will either validate or reject their submitted application package. A third and final e-mail message is generated once the applicant's application package has passed validation and the grantor agency has confirmed receipt of the application.

Unsuccessful Submissions: If an application submission was unsuccessful, the **applicant** must:

1. Track submission and verify the submission status (tracking should be done initially regardless of rejection or success).

a. If the status states "rejected," be sure to save time stamped, documented rejection notices, and do #2a or #2b

2. Check emails from both Grants.gov and NIH eRA Commons for rejection notices.

a. If the deadline has passed, he/she should email the Grants Management contact listed in the Agency Contacts section of this announcement explaining why the submission failed.

b. If there is time before the deadline, correct the problem(s) and resubmit as soon as possible.

Due Date for Applications 03/14/2022

03/14/2022

Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date.

10. Funding Restrictions

Expanded Authority:

For more information on expanded authority and pre-award costs, go to <https://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf> and speak to your GMS.

All HHS/CDC awards are subject to the federal regulations, in 45 CFR Part 75, terms and conditions, and other requirements described in the HHS Grants Policy Statement. Pre-award costs may be allowable as an expanded authority, but only if authorized by CDC.

Public Health Data:

CDC requires that mechanisms for, and cost of, public health data sharing be included in grants, cooperative agreements, and contracts. The cost of sharing or archiving public health data may also be included as part of the total budget requested for first-time or continuation awards.

Data Management Plan:

Fulfilling the data-sharing requirement must be documented in a Data Management Plan (DMP) that is developed during the project planning phase prior to the initiation of generating or collecting public health data and must be included in the Resource Sharing Plan(s) section of the PHS398 Research Plan Component of the application.

Applicants who contend that the public health data they collect or create are not appropriate for release must justify that contention in the DMP submitted with their application for CDC funds (for example, privacy and confidentiality considerations, embargo issues).

Recipients who fail to release public health data in a timely fashion will be subject to procedures normally used to address lack of compliance (for example, reduction in funding, restriction of funds, or award termination) consistent with 45 CFR 74.62 or other authorities as appropriate. For further information, please see: <https://www.cdc.gov/grants/additional-requirements/ar-25.html>

Human Subjects:

Funds relating to the conduct of research involving human subjects will be restricted until the appropriate assurances and Institutional Review Board (IRB) approvals are in place. Copies of all current local IRB approval letters and local IRB approved protocols (and CDC IRB approval letters, if applicable) will be required to lift restrictions.

If the proposed research project involves more than one institution and will be conducted in the United States, awardees are expected to use a single Institutional Review Board (sIRB) to conduct the ethical review required by HHS regulations for the Protections of Human Subjects Research, and include a single IRB plan in the application, unless review by a sIRB would be prohibited by a federal, tribal, or state law, regulation, or policy or a compelling justification based on ethical or human subjects protection issues or other well-justified reasons is provided. Exceptions will be reviewed and approved by CDC in accordance with Department of Health and Human Services (DHHS) Regulations (45 CFR Part 46), or a restriction may be placed on the award. For more information, please contact the scientific/research contact included on this NOFO.

Note: The sIRB requirement applies to participating sites in the United States. Foreign sites participating in CDC-funded, cooperative research studies are not expected to follow the requirement for sIRB.

Protection of Human Subjects and Personally Identifiable Information

The Research Strategy section of the application is expected to clearly describe the type, source, access to, and protections of the data and human subjects participating in the study. Access to non-publicly available, previously collected data must be clearly described in the Research Strategy and documented with a signed Data Sharing Agreement or Letter of Support. Access to publicly available, previously collected data must be clearly described in the Research Strategy.

Protection of previously collected data includes, but is not limited to, protection of personally identifiable information from loss and/or misuse.

The application is expected to identify each performance site that will be conducting human subjects research and include the FWA number for the applicant institution and each performance site. Research conducted with more than one institution will be expected to use a single Institutional Review Board (sIRB) to conduct the ethical review required by HHS regulations. See *Section IV. Application and Submission Information, 10 Funding Restrictions, Human Subjects* for details.

Data Management Plan

Applicants should develop and include, as part of the application's Resource Sharing Plan section of the PHS 398 Research Plan Component, a data management plan that meets the requirements of AR-25 using their own template. Applicants funded under this NOFO will be required to use NCIPC's Data Management Plan Template, OMB NO: 0920-1301 (Exp. Date: 06/30/2023) to make revisions to the DMP as required during the award's project period.

Indirect Cost Rate Agreement

If requesting indirect costs in the budget based on a federally negotiated rate, a copy of the indirect cost rate agreement is required. Include a copy of the current negotiated federal indirect cost rate agreement or cost allocation plan approval letter.

11. Other Submission Requirements and Information

Risk Assessment Questionnaire Requirement

CDC is required to conduct pre-award risk assessments to determine the risk an applicant poses to meeting federal programmatic and administrative requirements by taking into account issues such as financial instability, insufficient management systems, non-compliance with award conditions, the charging of unallowable costs, and inexperience. The risk assessment will include an evaluation of the applicant's CDC Risk Questionnaire, located at <https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf>, as well as a review of the applicant's history in all available systems; including OMB-designated repositories of government-wide eligibility and financial integrity systems (see 45 CFR 75.205(a)), and other sources of historical information. These systems include, but are not limited to: FAPIIS (<https://www.fapiis.gov/>), including past performance on federal contracts as per Duncan Hunter National Defense Authorization Act of 2009; Do Not Pay list; and System for Award Management (SAM) exclusions.

CDC requires all applicants to complete the Risk Questionnaire, OMB Control Number 0920-1132 annually. This questionnaire, which is located at <https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf>, along with supporting documentation must be submitted with your application by the closing date of the Notice of Funding Opportunity Announcement. If your organization has completed CDC's Risk Questionnaire within the past 12 months of the closing date of this NOFO, then you must submit a copy of that questionnaire, or submit a letter signed by the authorized organization representative to include the original submission date, organization's EIN and DUNS.

When uploading supporting documentation for the Risk Questionnaire into this application package, clearly label the documents for easy identification of the type of documentation. For example, a copy of Procurement policy submitted in response to the questionnaire may be labeled using the following format: Risk Questionnaire Supporting Documents _ Procurement Policy.

Duplication of Efforts

Applicants are responsible for reporting if this application will result in programmatic, budgetary, or commitment overlap with another application or award (i.e., grant, cooperative agreement, or contract) submitted to another funding source in the same fiscal year. Programmatic overlap occurs when (1) substantially the same project is proposed in more than one application or is submitted to two or more funding sources for review and funding consideration or (2) a specific objective and the project design for accomplishing the objective are the same or closely related in two or more applications or awards, regardless of the funding source. Budgetary overlap occurs when duplicate or equivalent budgetary items (e.g., equipment, salaries) are requested in an application but already are provided by another source. Commitment overlap occurs when an individual's time commitment exceeds 100 percent, whether or not salary support is requested in the application. Overlap, whether programmatic, budgetary, or commitment of an individual's effort greater than 100 percent, is not permitted. Any overlap will be resolved by the CDC with the applicant and the PD/PI prior to award.

Report Submission: The applicant must upload the report under "Other Attachment Forms." The document should be labeled: "Report on Programmatic, Budgetary, and Commitment Overlap."

Application Submission

Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. **PAPER APPLICATIONS WILL NOT BE ACCEPTED.**

Applicants must complete all required registrations before the application due date. Section III.6 "Required Registrations" contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically (http://grants.nih.gov/grants/guide/url_redirect.htm?id=11144).

Important reminders:

All Senior/Key Personnel (including any Program Directors/Principal Investigators (PD/PIs) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to CDC.

It is also important to note that for multi-project applications, this requirement also applies to the individual components of the application and not to just the Overall component.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

PLEASE NOTE: For applications due on or after April 4, 2022, applicants must have a unique entity identifier (UEI) at the time of application submission. In preparation for the federal government's April 4, 2022, transition from the Data Universal Numbering System (DUNS) to the Unique Entity Identifier (UEI), applicants must obtain a UEI. The UEI is generated as part of SAM.gov registration. Current SAM.gov registrants have already been assigned their UEI and can view it in SAM.gov and grants.gov. Additional information is available on the [GSA website](#), [SAM.gov](#), and [Grants.gov-Finding the UEI](#).

If the applicant has an FWA number, enter the 8-digit number. Do not enter the letters "FWA" before the number. If a Project/Performance Site is engaged in research involving human subjects, the applicant organization is responsible for ensuring that the Project/Performance Site operates under and appropriate Federal Wide Assurance for the protection of human subjects and complies with 45 CFR Part 46 and other CDC human subject related policies described in Part II of the SF 424 (R&R) Application Guide and in the HHS Grants Policy Statement.

See more resources to avoid common errors and submitting, tracking, and viewing applications:

- http://grants.nih.gov/grants/ElectronicReceipt/avoiding_errors.htm
- http://grants.nih.gov/grants/ElectronicReceipt/submit_app.htm
- https://era.nih.gov/files/ASSIST_user_guide.pdf
- <http://era.nih.gov/erahelp/ASSIST/>

Upon receipt, applications will be evaluated for completeness by the CDC Office of Grants Services (OGS) and responsiveness by OGS and the Center, Institute or Office of the CDC. Applications that are incomplete and/or nonresponsive will not be reviewed.d/////

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process. As part of the CDC mission ([http:// www.cdc.gov/ about/ organization/ mission.htm](http://www.cdc.gov/about/organization/mission.htm)), all applications submitted to the CDC in support of public health research are evaluated for scientific and technical merit through the CDC peer review system.

Overall Impact

Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

- To what extent does the proposed research objective match that of this funding announcement?
- If successfully completed, to what extent will the proposed activities advance current knowledge and build the evidence base of effective strategies that link people in recovery for illicit substance use disorders to recovery support services available within their community and, if needed, re-link people to such services following resumption of illicit substance use?
- To what extent will the proposed project address the needs of people within communities experiencing disproportionate burden of illicit substance use and overdose (including but not limited to those experiencing reduced economic stability; people experiencing homelessness, a mental health condition, chronic pain, incarceration or recent release from incarceration, limited educational attainment, access or quality, limited healthcare access or quality, limited access to substance use treatment or limited health literacy; people with disabilities; people from non-English speaking populations, tribal populations, rural communities and other geographically underserved areas, racial/ethnic minority groups, sexual and gender minority groups, people with a history of substance use disorders and/or overdose)?
- To what extent does the application balance innovation with an approach likely to provide relevant results within the 3-year project period?
- If successfully implemented, what is the likelihood that the proposed strategy being evaluated will prevent or reduce fatal and nonfatal overdose involving illicit substances?

- If successfully implemented, what is the likelihood that the proposed strategy being evaluated will increase the probability that persons in recovery from illicit substance use disorders maintain recovery and/or increase return to care for illicit substance use disorders following resumption of illicit substance use when applicable?
- Does the application propose research that, regardless of the scientific or technical merit, will be excluded from funding consideration? This includes the following types of applications:
 - Applications submitted that do not include both a clearly defined process evaluation and a clearly defined outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use.
 - Applications that propose evaluating strategies, programs or policies linking, or re-linking, people to recovery support services that solely focus on medical services and do not also link to other recovery support services.

Investigator(s)

Are the PD/PIs, collaborators, and other researchers well suited to the project? Have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

- Are the PD/PIs, collaborators, and other researchers well suited to the project? Have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
- To what extent do the PI/Co-I team have sufficient prior experience conducting empirical research on illicit substance use disorders, overdose, and evaluation of strategies to prevent such outcomes – i.e., research consistent with that which is proposed in the application?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

- To what extent does the proposed research demonstrate a reasonable potential of meeting the purpose and Research Objectives of this NOFO?
- To what extent does the proposal include innovative methods for conducting both a process and outcome evaluation, and scale-up of an intervention strategy?

- To what extent does the proposal leverage existing programmatic efforts to build the evidence for selected strategies?
- Is the proposed research innovative or novel and yet offer a reasonable potential of meeting the Purpose and Research Objectives of this NOFO?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed?

If the project involves clinical research, are there plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

- Is the research plan appropriate for the specific research objective proposed for evaluation in the application?
- To what extent is the application's proposed linkage strategy adequately supported by theory or empirical evidence?
- To what extent does the application address health inequities in its approach (e.g., strategies, measures, populations at increased risk)?
- Does the applicant propose using a rigorous evaluation design that includes data analytic plans appropriate to the research design and hypotheses?
- To what extent does the approach demonstrate the ability to access the necessary data for the evaluation?
- Are these data appropriate for documenting the expected changes in the project period proposed for the study?
- To what extent does is proposed process evaluation described and will the data collected facilitate successful translation of the linkage strategies?
- Does the application's proposed strategy assure sample retention and adequate statistical power to produce meaningful results, including for subpopulations?
- To what extent does the design address threats to validity and the ability to identify the key components?
- To what extent does the applicant clearly describe how findings can be immediately translated to action to prevent fatal and nonfatal overdose and/or increase maintenance of recovery from illicit substance use disorders and/or increase return to care for illicit substance use disorders when applicable?
- To what extent does the Research Strategy section of the application clearly describe the roles and responsibilities of each partner involved in data collection and/or the effectiveness evaluation?
- To what extent does the applicant provide the best available research for all recovery support services included in the linkage strategies?
- To what extent does the applicant propose linkage to at least one evidence-based recovery support service?

- Does at least one recovery support service linked to meet the following definition for evidence-based?
 - (1) meta-analyses or systematic reviews have found the strategy to be effective at reducing overdose and/or factors that increase overdose risk; (2) evidence from a scientifically rigorous experimental study, such as a randomized controlled trial, demonstrates the strategy’s effectiveness in reducing overdose and/or factors that increase overdose risk; or (3) multiple observational studies from U.S. settings indicate the strategy’s ability to reduce overdose or mitigate and reduce factors that increase overdose risk.
- To what extent does the application propose linking people to recovery support services currently available in their community?
- To what extent does the application propose to re-link people to recovery support services following resumption of illicit substance use?
- Does the applicant propose linking people to recovery support services that solely focus on medical services?
- Does the applicant propose both a clearly defined process and a clearly defined outcome evaluation of linkage strategies, programs, or policies?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

- If the application involves collaborations or partnerships, to what extent does the research strategy provide evidence of collaboration or partnership throughout the application?
- Does the applicant provide a description of the duties, percentage-of-time commitments, and responsibilities of project personnel including clear lines of authority and supervisory capacity over the behavioral, administrative, data management, and statistical aspects of the research?
- To what extent does the applicant provide evidence of access to and support from systems and organizations in which the strategies are being implemented (e.g., health systems, criminal justice settings, community settings)?
- To what extent is the nature of each entity’s involvement sufficient and appropriate for the successful completion of the project as a whole, including strategy implementation and data access for evaluation?
- To what extent does the application demonstrate access to the data, or include a plan for accessing the data, necessary to complete the proposed research within the proposed period of performance?
- To what extent does the Research Strategy clearly describe the working relationships between the applicant institution and all partner organizations?
- To what extent does the Research Strategy clearly describe the involvement and scope of work each partner is willing to complete to ensure the success of the proposed research within the proposed project period?

- To what extent are the relationships and activities of the partnerships described in the Research Strategy documented by a signed Data Sharing Agreement, Letter of Support, or Memorandum of Understanding that clearly delineates the intent and capabilities of each partnership?

2. Additional Review Criteria

As applicable for the project proposed, *reviewers will evaluate* the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but *will not give separate scores* for these items.

Protections for Human Subjects

If the research involves human subjects but does not involve one of the six categories of research that are exempt under [45 CFR Part 46](#), the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the HHS/CDC Requirements under AR-1 Human Subjects Requirements (<https://www.cdc.gov/grants/additional-requirements/ar-1.html>).

If your proposed research involves the use of human data and/or biological specimens, you must provide a justification for your claim that no human subjects are involved in the Protection of Human Subjects section of the Research Plan.

Inclusion of Women, Minorities, and Children

When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the policy on the Inclusion of Women and Racial and Ethnic Minorities in Research (https://www.cdc.gov/maso/Policy/Policy_women.pdf and the policy on the Inclusion of Persons Under 21 in Research (<https://www.cdc.gov/maso/Policy/policy496.pdf>).

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following four points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 4) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate

Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section (<https://grants.nih.gov/grants/olaw/VASchecklist.pdf>).

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Dual Use Research of Concern

Reviewers will identify whether the project involves one of the agents or toxins described in the US Government Policy for the Institutional Oversight of Life Sciences Dual Use Research of Concern, and, if so, whether the applicant has identified an IRE to assess the project for DURC potential and develop mitigation strategies if needed.

For more information about this Policy and other policies regarding dual use research of concern, visit the U.S. Government Science, Safety, Security (S3) website at: <http://www.phe.gov/s3/dualuse>. Tools and guidance for assessing DURC potential may be found at: <http://www.phe.gov/s3/dualuse/Pages/companion-guide.aspx>.

3. Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.

Applications from Foreign Organizations

N/A

Resource Sharing Plan(s)

HHS/CDC policy requires that recipients of grant awards make research resources and data readily available for research purposes to qualified individuals within the scientific community after publication. Please see: <https://www.cdc.gov/grants/additional-requirements/ar-25.html>

New additional requirement: CDC requires recipients for projects and programs that involve data collection or generation of data with federal funds to develop and submit a Data Management Plan (DMP) for each collection of public health data.

Investigators responding to this Notice of Funding Opportunity should include a detailed DMP in the Resource Sharing Plan(s) section of the PHS 398 Research Plan Component of the application. The [AR-25](#) outlines the components of a DMP and provides additional information for investigators regarding the requirements for data accessibility, storage, and preservation.

The DMP should be developed during the project planning phase prior to the initiation of collecting or generating public health data and will be submitted with the application. The submitted DMP will be evaluated for completeness and quality at the time of submission.

The DMP should include, at a minimum, a description of the following:

- A description of the data to be collected or generated in the proposed project;
- Standards to be used for the collected or generated data;

- Mechanisms for, or limitations to, providing access to and sharing of the data (include a description of provisions for the protection of privacy, confidentiality, security, intellectual property, or other rights - this section should address access to identifiable and de-identified data);
- Statement of the use of data standards that ensure all released data have appropriate documentation that describes the method of collection, what the data represent, and potential limitations for use; and
- Plans for archiving and long-term preservation of the data, or explaining why long-term preservation and access are not justified (this section should address archiving and preservation of identifiable and de-identified data).

Applications submitted without the required DMP may be deemed ineligible for award unless submission of DMP is deferred to a later period depending on the type of award, in which case, funding restrictions may be imposed pending submission and evaluation.

CDC OMB approved templates may be used (e.g. NCCDPHP template <https://www.cdc.gov/chronicdisease/pdf/nofo/DMP-Template-508.docx>)

Other examples of DMPs may be found here USGS, <http://www.usgs.gov/products/data-and-tools/data-management/data-management-plans>

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research. The applicant can obtain guidance for completing a detailed justified budget on the CDC website, at the following Internet address: <http://www.cdc.gov/grants/interestedinapplying/application-resources.html>

The budget can include both direct costs and indirect costs as allowed.

Indirect costs could include the cost of collecting, managing, sharing and preserving data.

Indirect costs on grants awarded to foreign organizations and foreign public entities and performed fully outside of the territorial limits of the U.S. may be paid to support the costs of compliance with federal requirements at a fixed rate of eight percent of modified total direct costs exclusive of tuition and related fees, direct expenditures for equipment, and subawards in excess of \$25,000. Negotiated indirect costs may be paid to the American University, Beirut, and the World Health Organization.

Indirect costs on training grants are limited to a fixed rate of eight percent of MTDC exclusive of tuition and related fees, direct expenditures for equipment, and sub-awards in excess of \$25,000.

If requesting indirect costs in the budget based on a federally negotiated rate, a copy of the indirect cost rate agreement is required. Include a copy of the current negotiated federal indirect cost rate agreement or cost allocation plan approval letter.

4. Review and Selection Process

Applications will be evaluated for scientific and technical merit by an appropriate peer review group, in accordance with CDC peer review policy and procedures, using the stated review criteria.

As part of the scientific peer review, all applications:

- Will undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review), will be discussed and assigned an overall impact/priority score.
- Will receive a written critique.

Applications will be assigned to the appropriate HHS/CDC Center, Institute, or Office. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review. The following will be considered in making funding recommendations:

- Scientific and technical merit of the proposed project as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.
- Consideration for meritorious applications that include signed Data Sharing Agreements, Letters of Support, or Memorandum of Understanding for each partnership described in the Research Strategy section of the application.
- Consideration for meritorious applications that contribute to a diverse mix of strategies in proposed research to evaluate the effectiveness of strategies to link or re-link individuals to recovery support services available within their community, as evidenced by the Research Strategy section of the application's research plan.
- Consideration for meritorious applications that contribute to a geographic balance of proposed projects, as evidenced by the congressional district of the applicant organization, to broaden the distribution of awards.
- Consideration for applicant organizations from or conducting research in collaboration or partnership with Minority Serving Educational Institutions (MSIs) i.e., Hispanic Serving Institutions (HSIs), Historically Black Colleges and Universities (HBCUs), Tribal Colleges and Universities (TCUs), or Alaska Native and Native Hawaiian Serving Institutions, as [defined by the U.S. Department of Education](#), and as evidenced by MSI inclusion in the SF-424 Senior/Key Personnel form, to broaden distribution of awards.
- Consideration for applications in which the contact PD/PI meets NIH Early Stage Investigator (ESI) status, as verified by the [NIH Determination of Investigator](#) process, to broaden distribution of awards.
- Exclusion from funding consideration, regardless of the scientific or technical merit of the proposed project, as evidenced by the Research Strategy section of the application's research plan:
 - **Applications submitted that do not include both a clearly defined process evaluation and a clearly defined outcome evaluation of linkage strategies, programs, or policies that link people in recovery for illicit substance use**

disorders to at least one evidence-based recovery support service available within their community and, if needed, *re-link* people to such services following resumption of illicit substance use.

- **Applications that propose evaluating strategies, programs or policies linking, or re-linking, people to recovery support services that solely focus on medical services and do not also link to other recovery support services.**

Review of risk posed by applicants.

Prior to making a Federal award, CDC is required by 31 U.S.C. 3321 and 41 U.S.C. 2313 to review information available through any OMB-designated repositories of government-wide eligibility qualification or financial integrity information as appropriate. See also suspension and debarment requirements at 2 CFR parts 180 and 376.

In accordance with 41 U.S.C. 2313, CDC is required to review the non-public segment of the OMB-designated integrity and performance system accessible through SAM (currently the Federal Recipient Performance and Integrity Information System (FAPIIS)) prior to making a Federal award where the Federal share is expected to exceed the simplified acquisition threshold, defined in 41 U.S.C. 134, over the period of performance. At a minimum, the information in the system for a prior Federal award recipient must demonstrate a satisfactory record of executing programs or activities under Federal grants, cooperative agreements, or procurement awards; and integrity and business ethics. CDC may make a Federal award to a recipient who does not fully meet these standards if it is determined that the information is not relevant to the current Federal award under consideration or there are specific conditions that can appropriately mitigate the effects of the non-Federal entity's risk in accordance with 45 CFR §75.207.

CDC's framework for evaluating the risks posed by an applicant may incorporate results of the evaluation of the applicant's eligibility or the quality of its application. If it is determined that a Federal award will be made, special conditions that correspond to the degree of risk assessed may be applied to the Federal award. The evaluation criteria is described in this Notice of Funding Opportunity.

In evaluating risks posed by applicants, CDC will use a risk-based approach and may consider any items such as the following:

- (1) Financial stability;
- (2) Quality of management systems and ability to meet the management standards prescribed in this part;
- (3) History of performance. The applicant's record in managing Federal awards, if it is a prior recipient of Federal awards, including timeliness of compliance with applicable reporting requirements, conformance to the terms and conditions of previous Federal awards, and if applicable, the extent to which any previously awarded amounts will be expended prior to future awards;
- (4) Reports and findings from audits performed under 45 CFR Part 75, subpart F, or the reports and findings of any other available audits; and
- (5) The applicant's ability to effectively implement statutory, regulatory, or other requirements imposed on non-Federal entities.

CDC must comply with the guidelines on government-wide suspension and debarment in 2 CFR part 180, and require non-Federal entities to comply with these provisions. These provisions restrict Federal awards, subawards and contracts with certain parties that are debarred, suspended or otherwise excluded from or ineligible for participation in Federal programs or activities.

5. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) and other pertinent information via the eRA Commons.

Section VI. Award Administration Information

1. Award Notices

Any applications awarded in response to this NOFO will be subject to the DUNS, SAM Registration, and Transparency Act requirements. If the application is under consideration for funding, HHS/CDC will request "just-in-time" information from the applicant as described in the HHS Grants Policy Statement (<https://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf>).

PLEASE NOTE: For applications due on or after April 4, 2022, applicants must have a unique entity identifier (UEI) at the time of application submission. In preparation for the federal government's April 4, 2022, transition from the Data Universal Numbering System (DUNS) to the Unique Entity Identifier (UEI), applicants must obtain a UEI. The UEI is generated as part of SAM.gov registration. Current SAM.gov registrants have already been assigned their UEI and can view it in SAM.gov and grants.gov. Additional information is available on the [GSA website](#), [SAM.gov](#), and [Grants.gov-Finding the UEI](#).

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the Grants Management Officer is the authorizing document and will be sent via email to the grantee's business official.

Recipient must comply with any funding restrictions as described in Section IV.11. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be allowable as an expanded authority, but only if authorized by CDC.

2. CDC Administrative Requirements

Overview of Terms and Conditions of Award and Requirements for Specific Types of Grants

Administrative and National Policy Requirements, Additional Requirements (ARs) outline the administrative requirements found in 45 CFR Part 75 and the HHS Grants Policy Statement and other requirements as mandated by statute or CDC policy. Recipients must comply with administrative and national policy requirements as appropriate. For more information on the Code of Federal Regulations, visit the National Archives and Records Administration: <https://www.archives.gov/>

Specific requirements that apply to this NOFO are the following:

[AR-1: Human Subjects Requirements](#)
[AR-2: Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research](#)
[AR-3: Animal Subjects Requirements](#)
[AR-9: Paperwork Reduction Act Requirements](#)
[AR-10: Smoke-Free Workplace Requirements](#)
[AR-11: Healthy People 2030](#)
[AR-12: Lobbying Restrictions](#)
[AR-13: Prohibition on Use of CDC Funds for Certain Gun Control Activities](#)
[AR-14: Accounting System Requirements](#)
[AR-16: Security Clearance Requirement](#)
[AR-17: Peer and Technical Reviews of Final Reports of Health Studies – ATSDR](#)
[AR-21: Small, Minority, And Women-owned Business](#)
[AR-22: Research Integrity](#)
[AR-24: Health Insurance Portability and Accountability Act Requirements](#)
[AR-25: Data Management and Access](#)
[AR-26: National Historic Preservation Act of 1966](#)
[AR-28: Inclusion of Persons Under the Age of 21 in Research](#)
[AR-29: Compliance with EO13513, “Federal Leadership on Reducing Text Messaging while Driving”, October 1, 2009](#)
[AR-30: Information Letter 10-006, - Compliance with Section 508 of the Rehabilitation Act of 1973](#)
[AR-31: Research Definition](#)
[AR-32: Appropriations Act, General Provisions](#)
[AR-33: United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern](#)
[AR-34: Accessibility Provisions and Non-Discrimination Requirements](#)
[AR-36: Certificates of Confidentiality](#)
[AR-37: Prohibition on certain telecommunications and surveillance services or equipment for all awards issued on or after August 13, 2020.](#)

Organization Specific ARs:

[AR-8: Public Health System Reporting Requirements](#)
[AR-15: Proof of Non-profit Status](#)
[AR 23: Compliance with 45 C.F.R. Part 87](#)

The full text of the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, 45 CFR 75, can be found at: <https://www.ecfr.gov/cgi-bin/text-idx?node=pt45.1.75>

To view brief descriptions of relevant CDC requirements visit: <https://www.cdc.gov/grants/additionalrequirements/index.html>

Additional CDC Award Requirements

The following Additional Requirements, some of which emphasize and expand upon those

above, will be required for all recipients funded under this NOFO.

All award recipients under this NOFO will be required to complete pre-registration of the research project(s) using publicly available platforms or ClinicalTrials.gov as applicable, consistent with the National Science Foundation's open science principles. The platform for intended pre-registration should be described in the Research Plan at the time of application.

All award recipients under this NOFO will be required to make data publicly available within 30 months of completing data collection, including to the extent possible making source code available to the public, and ensuring open access to research publications consistent with the National Science Foundation's open science principles.

The CDC will follow established implementation schedules and procedures for making grant awards under this NOFO in accordance with HHS and CDC Policy for Grant Program Administration and CDC Policy for Peer Review of Research and Scientific Programs to ensure that these awards support ideologically and politically unbiased research projects.

Data Management Plan. Applicants should develop and include, as part of the application's Resource Sharing Plan section of the PHS 398 Research Plan Component, a data management plan that meets the requirements of AR-25 using their own template. Applicants funded under this NOFO will be required to use NCIPC's Data Management Plan Template, OMB NO: 0920-1301 (Exp. Date: 06/30/2023) to make revisions to the DMP as required during the award's project period.

3. Additional Policy Requirements

The following are additional policy requirements relevant to this NOFO:

Should you successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identity, sexual orientation, and pregnancy). This includes taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting your legal obligation to take reasonable steps to ensure meaningful access to your programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.

- For information on your specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and taking appropriate steps to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment, see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>.
- For guidance on administering your project in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

HHS Policy on Promoting Efficient Spending: Use of Appropriated Funds for Conferences and Meetings, Food, Promotional Items and Printing Publications This policy supports the Executive Order on Promoting Efficient Spending (EO 13589), the Executive Order on Delivering and Efficient, Effective, and Accountable Government (EO 13576) and the Office of Management and Budget Memorandum on Eliminating Excess Conference Spending and Promoting Efficiency in Government (M-35-11). This policy applies to all new obligations and all funds appropriated by Congress. For more information, visit the HHS website at: <https://www.hhs.gov/grants/contracts/contract-policies-regulations/efficient-spending/index.html>.

Federal Funding Accountability and Transparency Act of 2006 Federal Funding Accountability and Transparency Act of 2006 (FFATA), P.L. 109–282, as amended by section 6202 of P.L. 110–252, requires full disclosure of all entities and organizations receiving Federal funds including grants, contracts, loans and other assistance and payments through a single, publicly accessible website, www.usaspending.gov. For the full text of the requirements, please review the following website: <https://www.frs.gov/>.

Plain Writing Act The Plain Writing Act of 2010, Public Law 111-274, was signed into law on October 13, 2010. The law requires that federal agencies use "clear Government communication that the public can understand and use" and requires the federal government to write all new publications, forms, and publicly distributed documents in a "clear, concise, well-organized" manner. For more information on this law, go to: <http://www.plainlanguage.gov/plLaw/index.cfm>.

Pilot Program for Enhancement of Employee Whistleblower Protections All applicants will be subject to a term and condition that applies the terms of 48 CFR section 3.908 to the award and requires that grantees inform their employees in writing (in the predominant native language of the workforce) of employee whistleblower rights and protections under 41 U.S.C. 4712.

Copyright Interests Provision This provision is intended to ensure that the public has access to the results and accomplishments of public health activities funded by CDC. Pursuant to applicable grant regulations and CDC's Public Access Policy, Recipient agrees to submit into the National Institutes of Health (NIH) Manuscript Submission (NIHMS) system an electronic version of the final, peer-reviewed manuscript of any such work developed under this award upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication. Also at the time of submission, Recipient and/or the Recipient's

submitting author must specify the date the final manuscript will be publicly accessible through PubMed Central (PMC). Recipient and/or Recipient's submitting author must also post the manuscript through PMC within twelve (12) months of the publisher's official date of final publication; however, the author is strongly encouraged to make the subject manuscript available as soon as possible. The recipient must obtain prior approval from the CDC for any exception to this provision.

The author's final, peer-reviewed manuscript is defined as the final version accepted for journal publication and includes all modifications from the publishing peer review process, and all graphics and supplemental material associated with the article. Recipient and its submitting authors working under this award are responsible for ensuring that any publishing or copyright agreements concerning submitted articles reserve adequate right to fully comply with this provision and the license reserved by CDC. The manuscript will be hosted in both PMC and the CDC Stacks institutional repository system. In progress reports for this award, recipient must identify publications subject to the CDC Public Access Policy by using the applicable NIHMS identification number for up to three (3) months after the publication date and the PubMed Central identification number (PMCID) thereafter.

Language Access for Persons with Limited English Proficiency Recipients of federal financial assistance from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. Recipients of federal financial assistance must take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency.

Dual Use Research of Concern On September 24, 2014, the US Government Policy for the Institutional Oversight of Life Sciences Dual Use Research of Concern was released. Grantees (foreign and domestic) receiving CDC funding on or after September 24, 2015 are subject to this policy. Research funded by CDC, involving the agents or toxins named in the policy, must be reviewed to determine if it involves one or more of the listed experimental effects and if so, whether it meets the definition of DURC. This review must be completed by an Institutional Review Entity (IRE) identified by the funded institution.

Recipients also must establish an Institutional Contact for Dual Use Research (ICDUR). The award recipient must maintain records of institutional DURC reviews and completed risk mitigation plans for the term of the research grant, cooperative agreement or contract plus three years after its completion, but no less than eight years, unless a shorter period is required by law or regulation.

If a project is determined to be DURC, a risk/benefit analysis must be completed. CDC will work collaboratively with the award recipient to develop a risk mitigation plan that the CDC must approve. The USG policy can be found at <http://www.phe.gov/s3/dualuse>.

Non-compliance with this Policy may result in suspension, limitation, restriction or

termination of USG-funding, or loss of future USG funding opportunities for the non-compliant USG-funded research project and of USG-funds for other life sciences research at the institution, consistent with existing regulations and policies governing USG-funded research, and may subject the institution to other potential penalties under applicable laws and regulations.

Data Management Plan(s)

CDC requires that all new collections of public health data include a Data Management Plan (DMP). For purposes of this announcement, “public health data” means digitally recorded factual material commonly accepted in the scientific community as a basis for public health findings, conclusions, and implementation.

This new requirement ensures that CDC is in compliance with the following; Office of Management and Budget (OMB) memorandum titled “Open Data Policy– Managing Information as an Asset” (OMB M-13-13); Executive Order 13642 titled “Making Open and Machine Readable the New Default for Government Information”; and the Office of Science and Technology Policy (OSTP) memorandum titled “Increasing Access to the Results of Federally Funded Scientific Research” (OSTP Memo).

The AR-25 <https://www.cdc.gov/grants/additional-requirements/ar-25.html> outlines the components of a DMP and provides additional information for investigators regarding the requirements for data accessibility, storage, and preservation.

Certificates of Confidentiality: Institutions and investigators are responsible for determining whether research they conduct is subject to Section 301(d) of the Public Health Service (PHS) Act. Section 301(d), as amended by Section 2012 of the 21st Century Cures Act, P.L. 114-255 (42 U.S.C. 241(d)), states that the Secretary shall issue Certificates of Confidentiality (Certificates) to persons engaged in biomedical, behavioral, clinical, or other research activities in which identifiable, sensitive information is collected. In furtherance of this provision, CDC-supported research commenced or ongoing after December 13, 2016 in which identifiable, sensitive information is collected, as defined by Section 301(d), is deemed issued a Certificate and therefore required to protect the privacy of individuals who are subjects of such research. Certificates issued in this manner will not be issued as a separate document, but are issued by application of this term and condition to this award. See Additional Requirement 36 to ensure compliance with this term and condition. The link to the full text is at: <https://www.cdc.gov/grants/additional-requirements/ar-36.html>.

4. Cooperative Agreement Terms and Conditions

Not Applicable (N/A)

5. Reporting

Recipients will be required to complete Research Performance Progress Report (RPPR) in eRA Commons at least annually (see <https://grants.nih.gov/grants/rppr/index.htm>; https://grants.nih.gov/grants/forms/report_on_grant.htm) and financial statements as required in the HHS Grants Policy Statement.

A final progress report, invention statement, equipment inventory list and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the HHS Grants Policy Statement.

Although the financial plans of the HHS/CDC CIO(s) provide support for this program, awards pursuant to this funding opportunity depend upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.

The Federal Funding Accountability and Transparency Act of 2006

(Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.

Compliance with this law is primarily the responsibility of the Federal agency. However, two elements of the law require information to be collected and reported by recipients:

- 1) Information on executive compensation when not already reported through the SAM Registration; and
- 2) Similar information on all sub-awards/ subcontracts/ consortiums over \$25,000. It is a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable CDC grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsr.gov on all subawards over \$25,000. See the HHS Grants Policy Statement (<https://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf>).

Technical Review and Summary Statement Response Requirements

Recipients will be required to electronically submit a response to the peer reviewers' comments and/or concerns, as documented in the Summary Statement, within 30 days of the notification of their initial award. Recipients will also be required to electronically submit a response to any progress concerns or areas for improvement noted on their annual Technical Review within the time period specified in the annual award continuation notice.

Annual Report Requirements

Recipients will be required to electronically submit an Annual Report within 90 to 120 days before the end of the current budget period. The Annual Report should include:

- A description of the completion status of each Specific Aim and/or research objective or milestone for the budget period.
- A complete list of the publications planned or completed to date - including status (e.g., published [include reference], in review, under development).
- A description of any changes made in the use of human subjects or IRB approval status.
- A description of any changes made in the Data Management Plan. Award recipients funded under this NOFO will be required to use NCIPC's Data Management Plan Template, OMB NO: 0920-1301 (Exp. Date: 06/30/2023) to make revisions to the DMP as required during the award's project period.

A. Submission of Reports

The Recipient Organization must provide HHS/CDC with an original, plus one hard copy of the following reports:

1. **Yearly Non-Competing Grant Progress Report**, is due 90 to 120 days before the end of the current budget period. The RPPR form (<https://grants.nih.gov/grants/rppr/index.htm>; https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf) is to be completed on the eRA Commons website. The progress report will serve as the non-competing continuation application. Although the financial plans of the HHS/CDC CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
2. **Annual Federal Financial Report (FFR) SF 425** (https://grants.nih.gov/grants/forms/report_on_grant/federal_financial_report_ffr.htm) is required and must be submitted through eRA Commons **within 90 days after the end of the calendar quarter in which the budget period ends.**
3. **A final progress report**, invention statement, equipment/inventory report, and the final FFR are required **90 days after the end of the period of performance.**

B. Content of Reports

1. Yearly Non-Competing Grant Progress Report: The grantee's continuation application/progress should include:
 - Description of Progress during Annual Budget Period: Current Budget Period Progress reported on the RPPR form in eRA Commons (<https://grants.nih.gov/grants/rppr/index.htm>). Detailed narrative report for the current budget period that directly addresses progress towards the Measures of Effectiveness included in the current budget period proposal.
 - Research Aims: list each research aim/project
 - a) Research Aim/Project: purpose, status (met, ongoing, and unmet), challenges, successes, and lessons learned
 - b) Leadership/Partnership: list project collaborations and describe the role of external partners.
 - Translation of Research (1 page maximum). When relevant to the goals of the research project, the PI should describe how the significant findings may be used to promote, enhance, or advance translation of the research into practice or may be used to inform public health policy. This section should be understandable to a variety of audiences, including policy makers, practitioners, public health programs, healthcare institutions, professional organizations, community groups, researchers, and other potential users. The PI should identify the research findings that were translated into public health policy or practice and how the findings have been or may be adopted in public health settings. Or, if they cannot be applied yet,

this section should address which research findings may be translated, how these findings can guide future research or related activities, and recommendations for translation. If relevant, describe how the results of this project could be generalized to populations and communities outside of the study. Questions to consider in preparing this section include:

- How will the scientific findings be translated into public health practice or inform public health policy?
- How will the project improve or effect the translation of research findings into public health practice or inform policy?
- How will the research findings help promote or accelerate the dissemination, implementation, or diffusion of improvements in public health programs or practices?
- How will the findings advance or guide future research efforts or related activities?

- Public Health Relevance and Impact (1 page maximum). This section should address improvements in public health as measured by documented or anticipated outcomes from the project. The PI should consider how the findings of the project relate beyond the immediate study to improved practices, prevention or intervention techniques, inform policy, or use of technology in public health. Questions to consider in preparing this section include:
 - How will this project lead to improvements in public health?
 - How will the findings, results, or recommendations been used to influence practices, procedures, methodologies, etc.?
 - How will the findings, results, or recommendations contribute to documented or projected reductions in morbidity, mortality, injury, disability, or disease?

- Current Budget Period Financial Progress: Status of obligation of current budget period funds and an estimate of unobligated funds projected provided on an estimated FFR.

- New Budget Period Proposal:
 - Detailed operational plan for continuing activities in the upcoming budget period, including updated Measures of Effectiveness for evaluating progress during the upcoming budget period. Report listed by Research Aim/Project.
 - Project Timeline: Include planned milestones for the upcoming year (be specific and provide deadlines).

- New Budget Period Budget: Detailed line-item budget and budget justification for the new budget period. Use the CDC budget guideline format.

- Publications/Presentations: Include publications/presentations resulting from this CDC grant only during this budget period. If no publication or presentations have been made at this stage in the project, simply indicate "Not applicable: No publications or presentations have been made."

- IRB Approval Certification: Include all current IRB approvals to avoid a funding restriction on your award. If the research does not involve human subjects, then please state so. Please provide a copy of the most recent local IRB and CDC IRB, if applicable. If any approval is still pending at time of APR due date, indicate the status in your narrative.
- Update of Data Management Plan: The DMP is considered a living document that will require updates throughout the lifecycle of the project. Investigators should include any updates to the project's data collection such as changes to initial data collection plan, challenges with data collection, and recent data collected. Applicants should update their DMP to reflect progress or issues with planned data collection and submit as required for each reporting period.
- Additional Reporting Requirements:

2. Annual Federal Financial Reporting The Annual Federal Financial Report (FFR) SF 425 is required and must be submitted through the Payment Management System (PMS) within 90 days after the end of the calendar quarter in which the budget period ends. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) cash transaction data.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to submit a letter explaining the reason and date by which the Grants Officer will receive the information.

The due date for final FFRs is 90 days after the Period of Performance end date.

Recipients must submit closeout reports in a timely manner. Unless the Grants Management Officer (GMO) of the awarding Institute or Center approves an extension, recipients must submit a final FFR, final progress report, and Final Invention Statement and Certification within 90 days of the end of grant period. Failure to submit timely and accurate final reports may affect future funding to the organization or awards under the direction of the same Project Director/Principal Investigator (PD/PI).

FFR (SF 425) instructions for CDC recipients are now available at https://grants.nih.gov/grants/forms/report_on_grant/federal_financial_report_ffr.htm. For further information, contact GrantsInfo@nih.gov. Additional resources on the Payment Management System (PMS) can be found at <https://pms.psc.gov>.

Organizations may verify their current registration status by running the "List of Commons Registered Organizations" query found at: https://era.nih.gov/registration_accounts.cfm. Organizations not yet registered can go to <https://commons.era.nih.gov/commons/> for

instructions. It generally takes several days to complete this registration process. This registration is independent of Grants.gov and may be done at any time.

The individual designated as the PI on the application must also be registered in the Commons. The PI must hold a PI account and be affiliated with the applicant organization. This registration must be done by an organizational official or their delegate who is already registered in the Commons. To register PIs in the Commons, refer to the eRA Commons User Guide found at: https://era.nih.gov/docs/Commons_UserGuide.pdf.

3. Final Reports: Final reports should provide sufficient detail for CDC to determine if the stated outcomes for the funded research have been achieved and if the research findings resulted in public health impact based on the investment. The grantee's final report should include:

- **Research Aim/Project Overview:** The PI should describe the purpose and approach to the project, including the outcomes, methodology and related analyses. Include a discussion of the challenges, successes and lessons learned. Describe the collaborations/partnerships and the role of each external partner.
- **Translation of Research Findings:** The PI should describe how the findings will be translated and how they will be used to inform policy or promote, enhance or advance the impact on public health practice. This section should be understandable to a variety of audiences, including policy makers, practitioners, public health programs, healthcare institutions, professional organizations, community groups, researchers and other potential end users. The PI should also provide a discussion of any research findings that informed policy or practice during the course of the Period of Performance. If applicable, describe how the findings could be generalized and scaled to populations and communities outside of the funded project.
- **Public Health Relevance and Impact:** This section should address improvements in public health as measured by documented or anticipated outcomes from the project. The PI should consider how the findings of the project related beyond the immediate study to improved practices, prevention or intervention techniques, or informed policy, technology or systems improvements in public health.
- **Publications; Presentations; Media Coverage:** Include information regarding all publications, presentations or media coverage resulting from this CDC-funded activity. Please include any additional dissemination efforts that did or will result from the project.
- **Final Data Management Plan:** Applicants must include an updated final Data Management Plan that describes the data collected, the location of where the data is stored (example: a repository), accessibility restrictions (if applicable), and the plans for long term preservation of the data.

6. Termination

CDC may impose other enforcement actions in accordance with 45 CFR 75.371- Remedies for Noncompliance, as appropriate.

The Federal award may be terminated in whole or in part as follows:

- (1) By the HHS awarding agency or pass-through entity, if the non-Federal entity fails to comply with the terms and conditions of the award;
- (2) By the HHS awarding agency or pass-through entity for cause;
- (3) By the HHS awarding agency or pass-through entity with the consent of the non-Federal entity, in which case the two parties must agree upon the termination conditions, including the effective date and, in the case of partial termination, the portion to be terminated; or
- (4) By the non-Federal entity upon sending to the HHS awarding agency or pass-through entity written notification setting forth the reasons for such termination, the effective date, and, in the case of partial termination, the portion to be terminated. However, if the HHS awarding agency or pass-through entity determines in the case of partial termination that the reduced or modified portion of the Federal award or subaward will not accomplish the purposes for which the Federal award was made, the HHS awarding agency or pass-through entity may terminate the Federal award in its entirety.

7. Reporting of Foreign Taxes (International/Foreign projects only)

A. Valued Added Tax (VAT) and Customs Duties – Customs and import duties, consular fees, customs surtax, valued added taxes, and other related charges are hereby authorized as an allowable cost for costs incurred for non-host governmental entities operating where no applicable tax exemption exists. This waiver does not apply to countries where a bilateral agreement (or similar legal document) is already in place providing applicable tax exemptions and it is not applicable to Ministries of Health. Successful applicants will receive information on VAT requirements via their Notice of Award.

B. The U.S. Department of State requires that agencies collect and report information on the amount of taxes assessed, reimbursed and not reimbursed by a foreign government against commodities financed with funds appropriated by the U.S. Department of State, Foreign Operations and Related Programs Appropriations Act (SFOAA) (“United States foreign assistance funds”). Outlined below are the specifics of this requirement:

1) Annual Report: The recipient must submit a report on or before November 16 for each foreign country on the amount of foreign taxes charged, as of September 30 of the same year, by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant during the prior United States fiscal year (October 1 – September 30), and the amount reimbursed and unreimbursed by the foreign government. [Reports are required even if the recipient did not pay any taxes during the reporting period.]

2) Quarterly Report: The recipient must quarterly submit a report on the amount of foreign taxes charged by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant. This report shall be submitted no later than two weeks following the end of each quarter: April 15, July 15, October 15 and January 15.

3) Terms: For purposes of this clause:

“Commodity” means any material, article, supplies, goods, or equipment;

“Foreign government” includes any foreign government entity;

“Foreign taxes” means value-added taxes and custom duties assessed by a foreign government on a commodity. It does not include foreign sales taxes.

4) Where: Submit the reports to the Director and Deputy Director of the CDC office in the country(ies) in which you are carrying out the activities associated with this cooperative agreement. In countries where there is no CDC office, send reports to VATreporting@cdc.gov.

5) Contents of Reports: The reports must contain:

- a. recipient name;
- b. contact name with phone, fax, and e-mail;
- c. agreement number(s) if reporting by agreement(s);
- d. reporting period;
- e. amount of foreign taxes assessed by each foreign government;
- f. amount of any foreign taxes reimbursed by each foreign government;
- g. amount of foreign taxes unreimbursed by each foreign government.

6) Subagreements. The recipient must include this reporting requirement in all applicable subgrants and other subagreements.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading or navigating forms)

Contact Center Phone: 800-518-4726

Email: support@grants.gov

Hours: 24 hours a day, 7 days a week; closed on Federal holidays

eRA Commons Help Desk (Questions regarding eRA Commons registration, tracking application status, post submission issues, FFR submission)

Phone: 301-402-7469 or 866-504-9552 (Toll Free)

TTY: 301-451-5939

Email: commons@od.nih.gov

Hours: Monday - Friday, 7am - 8pm U.S. Eastern Time

Scientific/Research Contact

Amanda Garcia-Williams, PhD, MPH

Scientific Program Official

Extramural Research Program Operations

National Center for Injury Prevention and Control (NCIPC)

Telephone: 770.488.3936

Email: AGarcia-Williams@cdc.gov

Peer Review Contact

Mikel Walters, PhD
Scientific Review Official
Extramural Research Program Operations
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
Email: mwalters@cdc.gov

Financial/Grant Management Contact(s)

Manal Ali
Grants Management Specialist
CDC Office of Grants Services
Telephone: 770-488-2706
Email: hf08@cdc.gov

Section VIII. Other Information

Other CDC Notices of Funding Opportunities can be found at www.grants.gov.

All awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections of the Public Health Service Act as amended and under the Code of Federal Regulations.

All awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement.

Successful recipients may be permitted expanded authorities in the administration of this award as provided for in the Code of Federal Regulations, Title 2, Subtitle A, Chapter II, Part 200, Subpart D, §200.308(d)(4). Specific authorities granted will be detailed in the official Notice of Award document.

Application Submission Process

Applications must be successfully submitted and complete all validation actions prior to 5PM ET of the application due date for this NOFO. Applicants are encouraged to submit the application in ASSIST three (3) business days before the stated due date to provide sufficient time to correct any errors. If post-submission errors are identified during the validation process, the errors must be corrected and the application must be re-submitted in ASSIST prior to 5PM ET of the application due date. HHS/CDC grant submission procedures do not provide a grace period beyond the grant application due date time to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems.

Applicants who encounter problems when submitting their applications must attempt to resolve them by contacting the NIH eRA Service desk and the Grants.gov Contact Center. See *Section IV. Application and Submission Information, 9 Submission Dates & Times* for contact information.

General Information

All applications submitted for this NOFO must be responsive to the specific requirements and objectives of this NOFO and must be submitted as a new application through www.grants.gov.

All applicants are advised to carefully review the responsiveness requirements and instructions on how applicants must document responsiveness in *Section III. Eligibility Information 5. Responsiveness* of this NOFO.

Applicants are encouraged to pay close attention to the Data Management Plan requirements listed in the NOFO and to keep these in mind while preparing their proposals.